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Abstract 
Alcohol use disorder is a chronic condition characterized by an inability to 
control alcohol intake. Recent research has shown that appetite-regulating 
hormones, ghrelin, and leptin, may play a role in alcohol craving. In addition, it is 
known that food and alcohol craving have overlapping receptors in the brain 
reward system. Ghrelin, a naturally occurring hormone in the human body, is 
produced mainly by ghrelinergic cells of the gastric mucosa. Once the hormone 
crosses the blood-brain barrier, it binds to growth hormone secretagogue 
receptor (ghrelin receptor) in the hypothalamus and stimulates the appetite and 
food intake. Leptin, a hormone produced from adipose tissue has an opposite 
effect to that of ghrelin and reduces hunger. Leptin and ghrelin work in tandem to 
maintain energy homeostasis in the body. It was demonstrated that antagonizing 
ghrelin receptor reduces alcohol craving thus making it a potential 
pharmacological target to treat alcohol use disorders.  
PF-5190457 is a highly selective, orally bioavailable ghrelin receptor 
inverse agonist developed by Pfizer. PF-5190457 was made available for 
research by the National Center for Advancing Translational Sciences (NCATS) 
under the NIH New Therapeutic Uses Pilot Program. Initial studies by Pfizer had 
shown that the compound is safe and well tolerated in healthy volunteers after 
oral administration. To date, the compound has completed Phase 1b clinical trials 
in nontreatment-seeking patients with alcohol use disorder. The plasma samples 
obtained from the study was evaluated for the pharmacokinetics of PF-5190457 
and its major hydroxy metabolite. In order to measure the concentration of the 
  
drug and its metabolite, a liquid chromatography tandem mass spectroscopy 
method (LC-MS/MS) was developed and validated as described in Manuscript I 
(to be submitted to Journal of Chromatography B: Biomedical Sciences and 
Applications). The manuscript describes a new LC-MS/MS method developed for 
this purpose and the assay was fully validated according to the FDA guidance 
document for bioanalytical methods. The analytes of interest were extracted from 
plasma with methanol using a simple protein precipitation technique, and tacrine 
was used as the internal standard. All the bioanalysis method parameters, i.e., 
sensitivity, specificity, linearity, accuracy, precision, matrix effect, recovery, and 
stability were within the recommended FDA guidelines. Incurred sample 
reanalysis (10% of the patient plasma samples) was performed to evaluate the 
repeatability of the new method and was found to be within the acceptance 
criteria. 
Manuscript II (to be submitted to Drug Metabolism and Disposition) 
describes the biotransformation of PF-5190457 (molecular weight: 513). Before 
this work in our lab, no information on the metabolism of the PF-5190457 in 
humans was available. Extensive LC-MS/MS profiling of plasma from Phase 1b 
study showed many circulating metabolites. Subsequent analysis revealed the 
presence of a significant hydroxy metabolite (m/z 529) along with minor 
glucuronide and hydroxy glucuronide metabolites. Further exploration of the 
fragmentation pattern of the major hydroxy metabolite (m/z 351 and m/z 225) 
suggested possible hydroxylation between the two nitrogen atoms of the drug. In 
parallel, in vitro experiments were conducted in human hepatic microsomes and 
  
cytosolic fractions to characterize the drug metabolism enzymes responsible for 
the formation of metabolites.  Preliminary data revealed the formation of hydroxy 
metabolite in the cytosol but not in the microsomes. The reaction was found to be 
independent of the presence of nicotinamide adenine dinucleotide phosphate 
(NADPH) in the incubation media. Addition of a non-selective CYP450 inhibitor 
(1-amino benzotriazole) inhibited the formation of all the minor metabolites but 
not the hydroxy metabolite. A comparative mass spectra analysis showed the 
presence of hydroxy metabolite in the human liver cytosol incubations which was 
previously found in human plasma. PF-5190457 was also incubated in 
hepatocytes leading to the formation of major and minor metabolites. Further 
addition of an aldehyde oxidase inhibitor (hydralazine) in hepatocytes completely 
inhibited the formation of the hydroxy metabolite indicating the involvement of 
aldehyde oxidase in the metabolism of the PF-5190457. The hydroxy metabolite 
was also found in incubations conducted with PF-5190457 and cytosol from 
different animal species. The aldehyde oxidase metabolite of PF-5190457 was 
biosynthesized, from female mouse liver cytosol and the structure of the 
metabolite was confirmed using NMR analysis indicating the hydroxylation 
position to be on the pyrimidine ring between the two nitrogen atoms. Literature 
shows both aldehyde and xanthine oxidase share substrate specificity. Specific 
inhibitors of both the enzymes were used to identify their involvement in the 
metabolism of the drug. Raloxifene and febuxostat were used as selective 
aldehyde oxidase and xanthine oxidase inhibitor, in human liver cytosol 
incubations with PF-5190457 respectively. The data from inhibition study 
  
suggested a role for both the enzymes in the biotransformation of the drug with 
aldehyde oxidase enzyme being dominant over xanthine oxidase. The kinetic 
parameters Km and Vmax for hydroxy metabolite formation in human liver 
cytosol were 42 ± 4 µM and 0.12 ± 0.003 nmol/min/mg protein, respectively. 
Aldehyde oxidase (AOX1) is gaining increased attention for its role in the 
metabolism of new drug candidates. A significant variability in the levels of the 
AOX1 protein expression in the human liver has been reported in published 
studies. We assessed the AOX1 levels in a novel repository of human liver 
(n=104) using mass spectroscopy as described in Manuscript III (to be 
submitted to Drug Metabolism and Disposition). The levels of AOX1 were 
estimated using traditional data-dependent acquisition and upcoming SWATH-
MS method. A strong and significant correlation (Spearman r-0.72, P<0.0001) 
was observed between the two methods making a case for the use of SWATH 
based methods in the field of drug metabolism. Expression levels of AOX1 
determined in our liver bank using MaxQuant (proteomics data analysis software) 
were found to be well within the literature reported range (2 - 49 pmol/mg total 
cytosolic protein). Further, we evaluated the effect of demographic factors 
(gender, age, ethnicity, drug usage, alcohol consumption, and smoking) and 
disease conditions (diabetes, non-alcoholic fatty liver disease) on the AOX1 
expression. We found no significant association between demographic factors 
with the expression of the AOX1 protein. Similarly, disease conditions were not 
found to influence the expression of AOX1 indicating other unidentified factors 
influencing the enzyme expression. 
  
Manuscript IV (to be submitted to British Journal of Clinical 
Pharmacology) outlines the pharmacokinetics data via non-compartmental 
analysis of PF-5190457 and its hydroxy metabolite. The concentrations of 
analytes from phase 1b trials were evaluated in N=12 patients at placebo, 50 and 
100 mg doses using validated LC-MS/MS method as described in Manuscript I. 
The half-life of the metabolite (~13 h) was found to be longer than the parent 
drug (~6 h). Additionally, the rate of formation of hydroxy metabolite was studied 
in cytosol prepared from 10 human liver samples. The rate of formation of 
hydroxy metabolite was found to be highly variable with a 20.5-fold (0.02 – 0.41 
nmol/min/mg protein) variation among the ten samples. Interestingly, the AOX1 
protein expression for same samples showed only 2.5-fold variability (16.8 - 44.1 
pmol/mg protein).  
In summary, an understanding of the enzymes responsible for the 
metabolism of a drug is essential to avoid drug-drug interactions or the presence 
of polymorphic enzymes interfering with the therapeutic outcome of the drug.  
Collectively, we for the first time determined the clinical pharmacokinetics of PF-
5190457 and its major metabolite (hydroxy metabolite) in alcoholic patients. 
Further studies suggested the involvement of aldehyde oxidase (major role) and 
xanthine oxidase (minor role) in the metabolism of the PF-5190457. Moreover, to 
examine the variability in the protein expression of the enzymes, we quantified 
AOX1 in a large liver databank. This work also makes a case for considering 
non-cytochrome-P450 enzymes in the early screening during drug discovery. 
Considering the longer half-life of metabolite than the parent, it will be warranted 
  
to investigate the pharmacological properties of hydroxy metabolite in future 
studies. 
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MANUSCRIPT-I: Analysis and Validation of an Assay for a Novel Ghrelin 
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LC-MS/MS in human plasma 
This manuscript has been prepared for submission as a research article to 
Journal of Chromatography B: Biomedical Sciences and Applications. 
 
MANUSCRIPT-II: The Role of Molybdenum-Containing Enzymes in the 
Biotransformation of PF-5190457 - a Novel Inverse Agonist of Ghrelin 
Receptor to Treat Alcoholism 
This manuscript has been prepared for submission as a research article to Drug 
Metabolism and Disposition. 
 
 
xi 
 
MANUSCRIPT-III: Assessment of AOX1 Levels Variability in Human Liver 
Cytosol with Label-Free Approach Using Mass Spectrometry 
This manuscript has been prepared for submission as a research article to Drug 
Metabolism and Disposition. 
 
MANUSCRIPT-IV: Clinical Pharmacokinetics of a Major Hydroxy Metabolite 
of PF-5190457, a Ghrelin Receptor Inverse Agonist- Evidence from In vivo 
and In vitro Studies 
This manuscript has been prepared for submission as a research article to British 
Journal of Clinical Pharmacology for publication.  
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Abstract 
PF-5190457 is a selective and potent ghrelin receptor inverse agonist 
presently undergoing clinical trials to treat alcoholism. We have established a 
selective and sensitive liquid chromatography-tandem mass spectrometry 
method for determination of PF-5190457 and its hydroxy metabolite (PF-
6870961) in human plasma and validated the assay according to FDA guidelines. 
Plasma samples were prepared by simple protein precipitation in methanol using 
tacrine as an internal standard (IS). Chromatographic separation was carried out 
on an Acquity UPLC BEH C18 (2.1mm×50mm) column with 1.7 μm particle size 
and 130 Å pore size column at a flow rate of 0.25 mL/min by a gradient method 
with a runtime of 11.30 min. Detection was performed using multiple reaction 
monitoring (MRM) at positive ion mode with two fragments for each analyte. 
Tacrine was found to be a suitable IS. The calibration curves were linear in the 
concentration range of 1-1000 ng/mL and 2-250 ng/mL for PF-5190457 and 
hydroxy metabolite respectively with a correlation coefficient ≥0.996. The inter-
assay precision and accuracy results obtained were within the FDA 
recommended guidelines. The analytes were found to be stable under varied 
stability conditions. The validated method was utilized to measure plasma 
concentration of PF-5190457 and its hydroxy metabolite in clinical studies. 
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Abbreviations  
CV Coefficient of variation  
IS Internal standard 
LLOQ Lower limit of quantification  
ME Matrix effect  
MeOH Methanol  
MRM Multiple reaction monitoring  
MS Mass spectrometry  
Mw Molecular weight  
PLs Phospholipids  
QCs Quality controls  
UPLC-MS/MS Ultra-performance liquid chromatography-tandem mass 
spectrometry 
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1. Introduction 
PF-5190457 (Fig. 1) is a novel peripherally acting inverse agonist of 
ghrelin receptor discovered by Pfizer pharmaceuticals. It is a small molecule with 
a molecular weight (Mw) 512.67 belonging to a member of spiro-azetidino-
piperidine series [1, 2]. Ghrelin, an endogenous peptide released from the 
stomach, is a ligand for growth hormone secretagogue receptor in the 
hypothalamus and regulates appetite and food intake in the body [3-5]. 
Antagonists of ghrelin could be potentially therapeutic to treat type 2 diabetes 
mellitus, eating disorders, obesity, and alcohol use disorder. They are believed to 
regulate these disorders by stimulating glucose-dependent insulin secretion, 
reduce food intake and craving for alcohol consumption respectively [6-12]. 
Clinical studies of PF-5190457 in healthy volunteers showed the drug is 
well-tolerated and exhibit linear pharmacokinetics [13].  Following oral 
administration, PF-5190457 is rapidly absorbed with a Tmax of 0.3-3 hour and its 
elimination half-life (t1/2 ) was ~8 h [13]. The metabolism pathway of PF-5190457 
suggests cytosolic oxidative reaction involving molybdenum co-factor containing 
enzymes, aldehyde oxidase, and xanthine oxidase, leading to the formation of a 
hydroxy metabolite (Figure 1b) (Manuscript II). PF-5190457 is currently 
undergoing clinical trials for the treatment for alcohol use disorder and type 2 
diabetes [8, 14]. 
Previously developed validated UPLC-MS/MS method in the laboratory 
did not include the hydroxy metabolite in the assay [14]. The current manuscript 
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demonstrates a simple and selective ultra performance liquid chromatography-
tandem mass spectroscopy (UPLC-MS/MS) for simultaneous determination of 
PF-5190457 and its hydroxy metabolite (PF-6870961) in human plasma using 
tacrine as an IS. The present method is established with the aim of determining 
PF-5190457 and its hydroxy metabolite in plasma samples obtained in clinical 
trials of patients with alcohol use disorder. 
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2. Materials and methods 
2.1. Chemicals and reagents 
 
PF-5190457 and tacrine (Mw 198.26) were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). PF-6870961 (hydroxy metabolite, Mw 528.23) was 
synthesized as described in the Manuscript II.  LC-MS grade methanol and 
formic acid were obtained from Fisher Scientific (Fair Lawn, NJ, USA). Blank 
K2EDTA human plasma from six subjects (three male, three female) was 
obtained from Bioreclamation (IVT Inc., Westbury, NY, USA). 
 
2.2. LC–MS/MS instrumentation, conditions and data processing 
 
The liquid chromatography separation was performed using an Acquity 
UPLC system comprising with a binary pump and a built-in column heater. A 10 
μL sample loop was used to inject samples in partial loop injection mode. 
Chromatography separation of analytes and IS was accomplished within 11.30 
min using gradient elution method using an Acquity UPLC BEH C18 (2.1 x 50 
mm, 1.7 µm particle size, 130Ǻ pore size) analytical column. An Acquity UPLC 
BEH C18 VanGuard pre-column (2.1 x 5 mm, 130Ǻ) was used prior to the 
analytical column. Mobile phase consisted of water: methanol 95:5% (v/v) 
containing 0.1% formic acid (A) and 100% methanol containing 0.1% formic acid 
(B). The column and autosampler temperature were kept at 40 °C and 10 °C, 
8 
 
respectively. The mobile phase was delivered at 0.25 mL/min flow rate, and the 
injection volume was 5 µL. The initial conditions of mobile phase (98% A, 2% B) 
was maintained for 2 min, B was increased from 2% to 80% over 8.30 min, and 
held till 9.30 min and returned to initial conditions, followed by a 2 min 
equilibration for a total run time of 11.30 min. 
Mass spectral analysis and quantification was carried out using multiple 
reaction monitoring (MRM) on a positive electrospray ionization mode with the 
following parameters: desolvation temperature of 350°C, desolvation gas flow 
650 L/h, capillary voltage 3.50 kV and cone voltage 20 V. The fragmentation 
pattern for PF-5190457 and IS were similar to previously reported methods [14-
16]. The optimized settings of mass spectrometer voltage and the retention time 
for analytes and internal standards with quantifier and qualifier fragments are 
summarized in Table 1. 
Data acquisition and processing were performed using MassLynx™ 
software (V 4.1) and TargetLynx™ tool respectively. Calibration curves were 
constructed by calculating the analyte to IS peak area ratio against analyte 
concentrations.  
 
2.3. Preparation of calibration standards, quality controls, and internal standard 
 
Sub stock solutions of PF-5190457 and hydroxy metabolite were separately 
prepared in 50% methanol to obtain a final concentration of 10 µg/mL and were 
stored at 4°C. Working stock solutions for calibration and quality controls were 
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prepared from the stock solution by adequate dilution using diluent (methanol: 
water, 50:50, v/v). The calibration standards and quality control samples were 
prepared by spiking appropriate amount of the standard working solutions into 
pooled K2EDTA human plasma with an organic solvent concentration less than 
5% of the final volume. An eight-point calibration curve with concentrations 
ranging from 1-1000 ng/mL and 2-250 ng/mL for PF-5190457 and hydroxy 
metabolite were prepared respectively.  Low, medium and high level QC samples 
were prepared for PF-5190457 (3, 200 and 750 ng/mL) and hydroxy metabolite 
(5, 25 and 200 ng/mL), respectively. A final working solution of 2.5 ng/mL tacrine 
(IS) in methanol was prepared. 
 
2.4. Sample extraction procedure 
 
Samples were prepared by a simple and direct protein precipitation. To 
0.050 mL of sample was added 0.200 mL of precipitating solution containing IS in 
methanol.  IS in methanol was added to all samples except blank. Control blank 
was extracted with IS whereas, the double blank was extracted in 100% 
methanol without any IS. The mixture was vortex mixed for 15 seconds, and then 
centrifuged at 10,000 rpm for 5 min. The clear supernatant (0.150 mL) was 
collected for further analysis.  
 
2.5. Method validation 
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The validation of this assay was performed according to the requirements 
as outlined in guidelines established by the US Food and Drug Administration 
(US FDA) to evaluate the method with respect to selectivity, sensitivity, linearity, 
accuracy, precision, recovery, matrix effect, recovery and stability of analytes 
[17]. 
2.5.1. Specificity and Sensitivity 
The method specificity was evaluated prior to the main validation batches 
for the presence of interference from endogenous compounds by screening 
blank plasma of six donors. The sensitivity of the assay was evaluated by 
analyzing blank plasma samples from six different donors and spiked plasma 
samples at the lower limit of quantification (LLOQ) levels of the analytes. 
2.5.2. Linearity, accuracy, and precision 
The linearity of the method was determined by analysis of standard plots 
associated with an eight-point calibration curve. Inter-assay precision and 
accuracy were calculated after the replicates in six different analytical runs. Peak 
area ratios of analytes to IS obtained from MRM were utilized for the construction 
of calibration curves, using least squares weighted (1/x) linear regression. Carry 
over test was assessed to demonstrate any carryover effect of analytes and IS. 
2.5.3. Matrix effect and Recovery 
11 
 
The components present in the matrix (plasma) can interfere with 
ionization efficiency by coeluting with analytes of interest [18]. Matrix effect for 
ion suppression and enhancement was assessed using blank and spiked human 
plasma using post column infusion experiment as described previously [14, 19]. 
The chromatograms can be visually evaluated to verify there are no interfering 
peaks at the elution time of analytes and IS. Likewise, the interference of 
phospholipids was determined as they are highly abundant endogenous 
compounds in biological membranes and can interfere with elution of analytes 
[20, 21]. The major transitions of phospholipids were monitored with the 
precursor ion (Q1) at m/z 496, 522, 524, 758 and 782 and product ion (Q3) with 
m/z 184 in the method [22]. Recovery was determined at two concentration 
levels (LQC and HQC) by comparing the peak area of the analytes from the pre-
extracted plasma standard with that obtained from post-extracted standard at the 
same concentration for the QC samples. 
2.5.4. Stability 
Stability of analytes were evaluated at two concentrations (LQC and 
HQC). The freeze–thaw stability was evaluated after undergoing three freeze 
thaw cycles, benchtop stability for 6 h and short-term stability was assessed after 
storage of the test samples at −80°C for 1 week. The autosampler storage 
stability was determined by storing the QC samples for ~48 h under autosampler 
condition (maintained at 10 C) before being analyzed.  
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2.5.5. Sample Reanalysis 
The results from previously validated UPLC-MS/MS method for 
determination of PF-5190457 in patient plasma samples (n=45) by the laboratory 
was correlated with the current method to test the assay’s ability to reproduce the 
data [14]. Plasma samples were obtained after oral administration of PF-5190457 
from phase 1b clinical study (NCT02039349) in alcoholic patients conducted at 
the clinical research center (NIH clinical center at Bethesda, MD, USA).  Incurred 
sample reanalysis (ISA) was performed to corroborate the results utilizing clinical 
samples. Samples (10% of the study size) around Cmax and terminal elimination 
phase were selected, reanalyzed and compared to the initial results obtained 
from clinical samples (described below). The results of repeated analysis were 
compared with original data, according to the following formula: (repeated 
sample − original sample) × 100/mean value. Two-thirds of the samples 
reanalyzed should be within ±20% between the two analyses [23].  
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3. Results and Discussion 
 
3.1. LC-MS assay 
The goal of this work was to develop and validate a simple and sensitive 
assay method for the simultaneous determination of PF-5190457 and its hydroxy 
metabolite in human plasma. The MS optimization was performed by direct 
infusion of solutions of PF-5190547, hydroxy metabolite and IS into the ESI 
source of the mass spectrometer. The best signal for both the analytes and IS 
was achieved using a positive ion mode. Protonated adducts for PF-5190547 
(m/z 513) and hydroxy metabolite (m/z 529) and their respective high intensity 
fragments (m/z 209 and m/z 225) were selected respectively for quantification. 
Several trials for chromatographic conditions were performed especially to 
select an optimal mobile phase and analytical C18 columns. These trials 
determined that the present method achieved an optimal degree of 
chromatographical separation for simultaneous separation of different hydroxy 
metabolites as well as the parent drug. 
 
3.2. Sample preparation optimization: 
 
A simple protein precipitation technique was utilized for the extraction of 
analytes and IS from the plasma samples. Acetonitrile, methanol, DMSO, 50% 
DMSO, 50% acetonitrile, 50% methanol mixture were investigated as organic 
solvents for stock solution preparation. It was noticed that the metabolite was 
14 
 
unstable in acetonitrile. Methanol was then chosen as the organic solvent for 
preparation of stock solution for the analytes and IS as well as only methanol 
was used in mobile phase. 
 
3.3. Selection of internal standard 
 
The stable isotopically labeled IS was not available for hydroxy metabolite 
and therefore we have demonstrated the suitability of readily available, cost-
effective compounds with no evidence of cross-talk with the analytes of interest 
in the current assay. Various compounds with similar LogP and Pka to that of 
analytes like indoprofen, chloroxazane, naproxen, tacrine and rifampicin were 
tested for selection of suitable IS for the assay. Tacrine was deemed to be the 
most suitable IS for quantification of PF-5190457 and hydroxy metabolite as it 
ionizes in the same polarity along with the respective analytes. 
 
3.4. Method Validation 
 
3.4.1. Specificity and selectivity 
The determination of PF-5190547, hydroxy metabolite and IS at their 
respective retention time were not affected by interference from co-extracted 
matrix components under the present LC–MS/MS conditions used in blank 
15 
 
plasma obtained from six different donors. Sensitivity was determined by 
comparing the baseline from blank plasma obtained from six different donors in 
comparison to that spiked with analytes at LLOQ. There was no interference 
observed from endogenous compounds. The representative extracted ion 
chromatograms of the analytes and the IS in human plasma are shown in Figure 
2. 
 
3.4.2. Linearity, Precision and Accuracy 
Calibration was found to be linear over the concentration range of 1-1000 
ng/mL for PF-5190547 and 2-250 ng/mL for hydroxy metabolite. The curve was 
fitted with linear regression using 1/x weighing function. The percentage 
deviation for PF-5190547 and hydroxy metabolite was less than 8.2% and 12.2% 
respectively (Table 2). The accuracy ranged from 96.2% to 113.2% for PF-
5190547 and 88.0% to 106.6% for hydroxy metabolite. The correlation 
coefficients (r2) for PF-5190547 and hydroxy metabolite were greater than 0.997 
and 0.996 respectively for all curves. Precision and accuracy for this method was 
controlled by calculating the inter-batch variations of LLOQ and QC samples at 
four concentrations for PF-5190547 (1, 3, 200 and 750 ng/mL) and hydroxy 
metabolite (2, 5, 25 and 200 ng/mL) as shown in Table 3. The inter-day precision 
of 2.4–7.4% for PF-5190547 and 3.6–6% for hydroxy metabolite. This method 
demonstrated inter-day accuracy 88–104.2% for PF-5190547 and 97.2–109.7% 
for the hydroxy metabolite. There was no between-sample carryover detected 
following the double blank injections.  
16 
 
 
3.4.3. Matrix effect and Recovery 
In the present study, the determination of PF-5190547 and hydroxy 
metabolite is not affected by co-extracted matrix components under the LC–
MS/MS conditions used Figure 3a. There was no interference from the 
phospholipids on the elution of analytes Figure 3b. The percent mean recovery 
for PF-5190547 and hydroxy metabolite ranged from 95-103%.  
 
3.4.4. Stability 
The data representing the stability in plasma at two concentration levels 
(LQC and HQC) for PF-5190547 and hydroxy metabolite for bench top stability, 
three freeze and thaw cycles, autosampler and short-term stability are given in 
Table 4. These results indicate that the analytes are stable in human plasma as 
the mean of the results of the tested samples were within the acceptance criteria 
of ± 15% of the nominal concentrations. These findings suggest no stability-
related problems would be expected during pharmacokinetic studies and 
analysis. 
 
3.4.5. Sample Reanalysis 
The patient samples (n=45) previously analyzed by UPLC-MS/MS method 
and subsequently analyzed by the current method were within ± 15.2% for PF-
5190457. The data generated by this method is reproducible despite differing the 
LC-MS/MS conditions. Method reproducibility was also determined by ISA (n=45) 
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following the FDA Guidance for Industry for parent and metabolite. More than 
two-thirds of the sample were within ± 20%. The incurred sample analysis 
indicates that both parent and its metabolite are stable within human plasma from 
subjects. Bland- Altman plot is recommended over Pearson’s or Spearman’s 
correlation coefficient for correlation analysis for ISA as the range of data can 
influence the correlation [23]. The correlation between both the LC-MS/MS 
methods and ISA for PF-5190457 and hydroxy metabolite are depicted via 
Bland–Altman plots in Figure 4(a)-(c). 
 
3.5. Method Application  
The present validated method has been successfully applied to measure 
the concentration of PF-5190547 and its hydroxy metabolite after oral 
administration (50 mg and 100 mg) in human plasma obtained from phase 1b 
pharmacokinetics alcoholic patients admited to the clinical research center (NIH 
clinical center at Bethesda) for three visits (placebo, a dose of 50 mg and a dose 
of 100 mg). The study was approved by the University of Rhode Island 
Institutional Review Board HU# 123.172. The participants have filled out the 
informed consent form prior to the study. The plasma concentration ranges of 
PF-5190547 and hydroxy metabolite were measurable within their calibration 
curves. Figure 5 represents plasma concentration time profile after an oral dose 
of 50 mg dose in a study subject. 
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4. Conclusion 
 
In this manuscript, we describe development of a sensitive LC–MS/MS for 
the accurate, precise and reliable measurement of PF-5190547 and its hydroxy 
metabolite in human plasma. This study demonstrates the suitability of tacrine as 
IS for accurate quantification of PF-5190547 and hydroxy metabolite. This 
method demonstrated adequate reliability and reproducibility of the results within 
the analytical range. We have shown that PF-5190547 and hydroxy metabolite 
are stable in human plasma under different storage conditions. This assay was 
successfully employed for determination concentration of PF-5190457 and the 
metabolite in a phase 1b clinical trial.   
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Tables Legend 
Table 1. Mass spectrometry parameters for analytes and IS 
Table 2. Summary of calibration standards from six validation runs 
Table 3. Summary of QC samples from six validation runs 
Table 4. Summary of stability studies 
 
Figures Legend 
Figure 1 (a) and (b). Structure of PF-5190457 and Hydroxy metabolite. 
Figure 2. Representative chromatograms of (a) drug-free plasma sample (b) 
plasma sample extracted with IS and (c) plasma sample spiked at lower limit of 
quantiﬁcation for PF-5190457 and hydroxy metabolite, and extracted with 2.5 
ng/mL of tacrine respectively. 
Figure 3(a). Chromatogram obtained with post column infusion shows no matrix 
effect at the retention times of analytes and IS. Arrows indicates region where the 
signal of compounds infused post-column is suppressed during the elution of 
endogenous matrix components (b) Chromatogram showing the peaks of 
analytes and corresponding IS along with key phospholipids. 
Figure 4. Bland–Altman plots for (a). the correlation of PF-5190457 samples 
(n=45) analyzed by LC-MS/MS by method 1 vs. the current LC/MS/MS Dashed 
lines represent 95% limits of agreement (lower = −13.7%, upper = 13%) (b) and 
(c) ISA (Incurred sample reanalysis) showing the correlation for original vs. 
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repeat analysis for PF-5190457 (lower = −2.7%, upper = 22.7%) and hydroxy 
metabolite (lower = −22%, upper = 11%) respectively. 
Figure 5. Representative graph showing plasma concentration time profiles for 
parent (PF-5190547) and hydroxy metabolite after the administration of 50 mg 
dose respectively in a study volunteer.  
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Table I-1. 
Mass spectrometry parameters for analytes and IS 
Compound Parent  
Ion 
(m/z) 
Daughter 
ion (m/z) 
Dwell 
(s) 
Cone 
(V) 
Collision 
energy 
(V) 
Retention 
Time 
(min) 
PF-
5190457 
513 209, 335 0.025 30, 30 44, 16 4.4 
Hydroxy 
metabolite 
529 225, 351 0.025 34, 32 40, 20 3.8 
Tacrine 199 170, 143 0.025 46, 42 30, 36 4.6 
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Table I-2. 
Summary of calibration standards from six validation runs 
PF-
5190457 
Nominal 
Conc. (ng/mL) 
Mean SD % Bias CV %Accuracy 
STD 1 1 1 0 0.9 3.9 99.1 
STD 2 2 1.9 0.2 -4.8 8.2 104.8 
STD 3 10 11.2 0.4 12 3.7 88 
STD 4 100 108.8 3.8 8.8 3.5 91.2 
STD 5 250 266.8 8.4 6.7 3.2 93.3 
STD 6 500 521.2 10.2 4.2 2 95.8 
STD 7 800 822.3 20.5 2.8 2.5 97.2 
STD 8 1000 936.4 20.3 -6.4 2.2 106.4 
r2 
 
0.997 
  
0.2 
 
Hydroxy 
metabolite 
Nominal 
Conc. (ng/mL) 
Mean SD % Bias CV %Accuracy 
STD 1 2 2.1 0.1 3.4 5.8 96.6 
STD 2 3.9 3.4 0.1 -12.9 2.5 112.9 
STD 3 7.8 6.9 0.8 -11.7 12.2 111.7 
STD 4 15.6 13.5 0.8 -13.2 5.8 111.6 
STD 5 31.5 28.3 0.9 -10.1 3 110.1 
STD 6 62.5 58.4 3.4 -6.6 5.7 106.6 
STD 7 125 127.6 1.6 2.1 1.2 97.9 
STD 8 250 256.7 2.4 2.7 0.9 97.3 
r2  0.996   0.3  
n=6 (one replicate for each of the six validation runs), %Accuracy=100−[(mean-
nominal)/nominal] *100, %CV calculated as (SD/mean) *100, %bias calculated 
as 100×(mean−nominal)/nominal 
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Table I-3. 
Summary of QC samples from six validation runs 
Analyte   LLOQ QC1 QC2 QC3 
P
F
-5
1
9
0
4
5
7
 
Nominal Conc (ng/mL) 1.0 3.0 200.0 750.0 
Inter-run Mean 1.0 2.9 224.0 776.6 
Inter-run SD 0.1 0.2 5.3 28.3 
Inter-run % Bias 4.9 -4.2 12.0 3.5 
Inter-run CV 11.4 7.6 2.4 3.6 
%Accuracy 95.1 104.2 88.0 96.5 
   LLOQ QC1 QC2 QC3 
H
y
d
ro
x
y
 m
e
ta
b
o
li
te
 Nominal Conc (ng/mL) 2.0 5.0 25.0 200.0 
Inter-run Mean 2.0 4.9 22.6 205.5 
Inter-run SD 0.1 0.2 0.8 9.8 
Inter-run % Bias 2.1 -2.6 -9.7 2.8 
Inter-run CV 6.0 4.7 3.6 4.8 
%Accuracy 97.9 102.6 109.7 97.2 
n=18 (three replicates for each of the six validation runs), 
%Accuracy=100−[(mean-nominal)/nominal] *100, %CV calculated as (SD/mean) 
*100, %bias calculated as 100×(mean−nominal)/nominal 
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Table I-4. 
Summary of stability studies 
  
  
  
Bench top  
(6h) 
Freeze thaw  
(3 cycles) 
Autosampler  
(36h) 
Short-term  
(1 week) 
    LQC HQC LQC HQC LQC HQC LQC HQC 
P
F
-5
1
9
0
4
5
7
 
Mean 3.0 795.0 2.7 782.2 2.8 759.1 3.0 759.3 
% Bias 0.3 6.0 -9.4 4.3 -5.3 1.2 -0.8 1.2 
% CV 9.6 3.7 6.4 4.2 2.2 3.1 2.1 3.1 
H
y
d
ro
x
y
 M
e
ta
b
o
li
te
  
Mean 5.0 215.2 4.8 222.3 -1.5 211.0 4.2 220.0 
% Bias -3.9 7.6 -5.9 11.1 -3.3 5.5 1.0 10.0 
% CV 7.7 2.8 7.0 0.9 8.2 3.8 4.6 0.8 
 
%CV calculated as (SD/mean) *100, %bias calculated as 
100×(mean−nominal)/nominal 
LQC and HQC for PF-5190547and hydroxy metabolite are 3 and 750 ng/mL, 5 
and 200 ng/mL respectively 
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Figure I-1 (a) and (b). Structure of PF-5190457 and hydroxy metabolite 
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Figure I-2. Representative chromatograms of (a) drug-free plasma sample (b) 
plasma sample extracted with IS and (c) plasma sample spiked at lower limit of 
quantiﬁcation for PF-5190457 and hydroxy metabolite, and extracted with 2.5 
ng/mL of tacrine respectively. 
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Figure I-3(a). Chromatogram obtained with post column infusion shows no 
matrix effect at the retention times of analytes and IS. Arrows indicates region 
where the signal of compounds infused post-column is suppressed during the 
elution of endogenous matrix components (b) Chromatogram showing the peaks 
of analytes and corresponding IS along with key phospholipids 
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Figure I-4 Bland–Altman plots for (a). the correlation of PF-5190457 samples 
(n=45) analyzed by LC-MS/MS by method 1 vs. the current LC/MS/MS (b) and 
(c) ISA (Incurred sample reanalysis) showing the correlation for original vs. 
repeat analysis for PF-5190457 and hydroxy metabolite respectively. All the plots 
indicate the percentage difference between the concentrations of analytes 
measured were within ±20%.   
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Figure I-5. Representative graph showing plasma concentration time profiles for 
parent (PF-5190547) and hydroxy metabolite after the administration of 50 mg 
dose respectively in a study volunteer.  
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Abstract 
PF-5190457 ((R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methylpyrimi-
din-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl) ethan-1-one), 
was identified as a potent and selective ghrelin receptor inverse agonist. The 
present study characterizes the routes of biotransformation of this compound in 
vivo and then further explores in vitro metabolism using subcellular fractions of 
human liver and primary hepatocytes. Following oral administration of PF-
5190457, hydroxyl metabolites were observed, including one that had not been 
observed in human liver microsomal incubations. This major hydroxy metabolite 
was biosynthesized using liver cytosol and the site of hydroxylation was shown to 
be on the pyrimidine using nuclear magnetic resonance spectroscopy.  The 
chemical inhibitors of AO (raloxifene) and XO (febuxostat) inhibited the formation 
of the major hydroxy metabolite in human liver cytosol. Both the enzymes were 
involved in the metabolism of the drug whereas, greater inhibition was observed 
to be achieved using AO inhibitor indicating AO to be a dominant enzyme. The 
Clint of the drug in human liver cytosol was 0.002 mL/min/mg protein. This study 
demonstrates the importance of considering the molybdenum-containing 
oxidases during the development of new drug entities. 
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Introduction 
Ghrelin is a 28 amino acid peptide released from the stomach fundus and has a 
key role in growth and energy balance in the body (Korbonits et al., 2004). It is an 
endogenous ligand binding to the growth hormone secretagogue receptor in the 
hypothalamus resulting in increased food intake and decreased energy 
expenditure (Kojima et al., 1999; Asakawa et al., 2001; Inui et al., 2004). Leptin 
has an opposite effect to that of ghrelin and both the hormones together regulate 
energy homeostasis in the body (Yildiz et al., 2004). Ghrelin is used as an 
orexigenic agent to stimulate food intake as shown in clinical studies (Nagaya et 
al., 2004; Neary et al., 2004; Nagaya et al., 2005). Moreover, intravenous ghrelin 
administration suppresses glucose dependent insulin secretion in healthy 
subjects (Tong et al., 2010). It has been observed that neurotransmitters and 
peptides regulating food intake can also influence craving for alcohol in alcoholic 
individuals (Leggio et al., 2011; Volkow et al., 2013). In a human study, 
intravenous administration of ghrelin (3 mcg/kg in 45 subjects) increased the 
craving towards alcohol in alcohol dependent heavy drinkers (Leggio et al., 
2014). Furthermore, in a rat study, it was demonstrated that antagonizing ghrelin 
receptor could prove as a potential target to treat alcohol addiction (Suchankova 
et al., 2013). Thus, inhibition of ghrelin and growth hormone secretagogue 
system can potentially lead to the discovery of novel pharmacological treatments 
for alcoholism. 
PF-5190457 ((R)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)-1-(2-(5-(6-methyl- 
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pyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-2,7-diazaspiro[3.5]nonan-7-yl)ethan-1-
one; Fig. 1) is a member of spiro-azetidino-piperidine series identified as a potent 
ghrelin receptor inverse agonist (Bhattacharya et al., 2014). It is presently 
undergoing clinical trials at the National Institutes of Health for the treatment of 
alcohol use disorder (Ghareeb et al., 2015; Kong et al., 2016). In healthy 
volunteers, PF-5190457 was observed to be well tolerated (Denney et al., 2017) 
and it was found to be safe in a phase 1b study in subjects with alcohol use 
disorder (Lee et al, to be submitted for publication). The absorption of the drug 
after oral administration was rapid with a Tmax of 0.3-3 h and the elimination half-
life (t1/2) was found to be ~8 h (Denney et al., 2017). 
Limited information is available on the biotransformation of PF-5190457. 
The assessment of metabolic pathways of a new drug is important as it helps to 
understand the pharmacokinetics and pharmacodynamics of the compound in 
human.  It is essential to identify the enzymes responsible for biotransformation, 
as this information contributes to an understanding of interindividual variability in 
pharmacokinetics that can be due to genetic polymorphism or drug-drug 
interactions. In addition, metabolites generated by these enzymes could be 
pharmacologically active or have off-target effects (Lin and Lu, 1997; Kumar and 
Surapaneni, 2001).  
The objective of the present study was to characterize the 
biotransformation of PF-5190457 in vitro and to identify the major human 
circulating metabolites. Specifically, the objectives include 1) to characterize the  
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circulating metabolites in vivo in human plasma, 2) to determine of formation of 
metabolites in vitro, in sub-cellular fractions of human liver and human 
hepatocytes, 3) to confirm the structure of identified metabolites by mass 
spectrometry and NMR analyses 4) to assess the kinetic parameters of the 
metabolite formation, and 5) to identify the enzyme/s responsible for the 
formation of the major circulating metabolite using specific inhibitors for each 
enzyme. 
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Materials and Methods 
Reagents.  
PF-5190457, raloxifene hydrochloride, febuxostat and tacrine (internal standard) 
were purchased from Sigma Aldrich (St. Louise, MO, USA).  Allopurinol was 
purchased from Toronto Research Chemicals (Toronto, Canada).  PF-5190457 
major hydroxy metabolite (also called PF-6870961) was biosynthesized as 
described below. Recombinant aldehyde oxidase (rAOX) was produced by Pfizer 
La Jolla, CA, USA). Dihydronicotinamide-adenine dinucleotide phosphate 
(NADPH) tetrasodium salt was obtained from Calbiochem (EMD Millipore, 
Billerica, MA). LC-MS grade methanol, acetonitrile and formic acid were 
purchased from Fisher Scientific (Fairlawn, NJ, USA). All other reagents and 
chemicals used in the study were of analytical grade and used without further 
purification. 
 
In Vivo Metabolite Profiling. 
Study Samples.  
Plasma samples obtained after oral administration of PF-5190457 from 
phase 1b clinical study (NCT02039349) in alcoholic patients conducted at the 
NIH Clinical Center (Bethesda, MD, USA) were analyzed by high-resolution mass 
spectrometry (HRMS) to identify the circulating metabolites. The study was 
approved by the University of Rhode Island Institutional Review Board HU# 
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123.172. The participants have filled out the informed consent form prior to the 
study. 
Sample Preparation. 
Pooled plasma samples from representative patients were prepared for 
metabolite profiling experiments at various sampling times (predose, early and 
late post dose). Plasma proteins were precipitated by methanol followed by 
vortex mixing and centrifugation at 1,700 g for 5 min. The supernatant was then 
transferred into a (Genevac, Valley Cottage, NY), evaporated for 4h, and then 
reconstituted in 30 μL methanol followed by 120 μL water. The reconstituted 
samples were spun in a microfuge for 3 min to remove particulates, and 10 μL of 
aliquot of the reconstituted solution was injected onto HRMS system. 
LC-TOF mass spectrometry 
Chromatographic separation for metabolite profiling was achieved using a 
Waters HSS T3 C18 column (1.8 μm; 2.1x100 mm; Waters Corp) connected to 
Thermo Accela HPLC pump, CTC Analytics autoinjector, a diode array detector 
(PDA or DAD) and a Thermo Orbitrap Elite high resolution mass spectrometer 
(HRMS) (Thermo Fisher Scientific Inc, Waltham, MA, USA). The mobile phase 
consisted of 10 mM ammonium acetate (A) and methanol (B) with a flow rate of 
0.35 mL/min. The gradient elution was started from 5% B, maintained for 0.5 min, 
increased to 50% B over 10 min, and then to 95% B over the next 2 min and 
finally decreased to 5% B to re-equilibrate the column with a total run time of 15 
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min. The MS detection was operated in positive ion electrospray (ES-positive) 
mode.  
 
In Vitro Biotransformation of PF-5190457 
Preparation of subcellular fractions 
Human liver tissues (n=104) were obtained from Xenotech (Lenexa, KS, 
USA). Microsomal (HLM) and cytosolic (HLC) fractions were prepared by 
differential ultracentrifugation from human liver as described previously (Jamwal 
et al., 2017). Total protein concentration for the HLM and HLC were determined 
using Pierce BCA (bicinchoninic acid) protein assay kit (Thermo Fisher Scientific 
Inc, Waltham, MA, USA) and the fractions were stored in -80°C until further 
analysis. 
HLM and HLC Incubations 
The in vitro metabolism of PF-5190457 was studied using HLM and HLC. 
PF-5190457 was incubated at relatively high concentrations (50-100 µM) with 
pooled HLM and HLC in a total volume of 50 µL of 100 mM potassium phosphate 
buffer (pH-7.4) such that the final concentration of methanol was less than 
0.25%. Incubations were conducted at 37°C in an oscillating water bath. The total 
protein concentration used for both HLM and HLC ranged from 0.05 - 2 mg/mL. 
PF-5190457 was also incubated in only 100 mM potassium phosphate buffer 
(pH-7.4) without HLM or HLC as control. Microsomal incubations were conducted 
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with and without the addition of NADPH. The reaction was terminated by addition 
of 200 µL of ice-cold methanol at various incubation times (0-120 min). 
Subsequently, the samples were centrifuged for 5 min at 10,000 rpm to remove 
the precipitated protein. 
LC-MS/MS analysis of HLM and HLC samples 
The supernatant obtained from the samples was analyzed using an 
Acquity UPLC coupled with a Xevo-TQ mass spectrometer (Waters Corp, 
Milford, MA, USA). Samples (5 μL) were injected onto a C18 column (Acquity 
UPLC BEH 2.1 x 50 mm) with 1.7 µm particle size and 130 Å porosity. A pre-
column (Acquity UPLC BEH C18, 2.1 x 5 mm) was connected prior to the 
analytical column. Mobile phase consisted of water: methanol 95:5% (v/v) 
containing 0.1% formic acid (A) and 100% methanol containing 0.1% formic acid 
(B). The column and autosampler temperature were kept at 40°C and 10°C, 
respectively. The mobile phase was delivered at 0.25 mL/min flow rate and the 
injection volume was 5 µL. Mobile phase initial condition of 98% solvent A, 2% 
solvent B was maintained for 2 min, but proportion of solvent B was increased to 
50% over 8.30 min, and then to 95% solvent B over the next 2 min and returned 
to the initial condition for equilibration. The total run time was 12.30 min. A full 
scan from 100-1200 Da was carried out in a positive electrospray ionization 
mode with the following parameters: desolvation temperature of 600°C, 
desolvation gas flow of 1000 L/h, capillary voltage of 3.50 kV and cone voltage of 
30 V. Similarly, single-ion monitoring for the [M+H] + ions of the anticipated  
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metabolites - hydroxy metabolite (513.2431+16), glucuronide (513.2431+176) 
and hydroxy glucuronide (513.2431+192) conjugates with daughter scan was 
performed. 
Hepatocytes incubations 
PF-05190457 was incubated in human hepatocytes with and without 1 
amino benzotriazole (ABT) - a pan CYP450 inhibitor and hydralazine - a selective 
probe inactivator of aldehyde oxidase (AO) respectively (Ortiz de Montellano and 
Mathews, 1981; Strelevitz et al., 2012).  
Incubations in liver cytosol of various species 
PF-5190457 was incubated at 20 µM, with pooled mouse (male and 
female), rat and monkey (male and female) liver cytosol (2 mg/mL) in a total 
volume of 1 mL potassium phosphate buffer (100 mM; pH 7.5). Incubations were 
performed at 37°C for 75 min and then stopped by addition of acetonitrile (5 mL). 
Samples were centrifuged at 1700 g for 5 min and the supernatant was 
evaporated in vacuo, reconstituted in 1% formic acid (0.2 mL) for analysis by 
HPLC-UV-MS. 
 
Biosynthesis and NMR Analysis 
PF-5190457 (20 µM) was incubated with female mouse liver cytosol (20 
mg/mL; Corning-Gentest, Woburn, MA) in 40 mL potassium phosphate buffer  
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(100 mM, pH 7.5) in a shaking water bath maintained at 37oC for 1.5 hr.  
The incubation was terminated with addition of CH3CN (40 mL) and the 
precipitated material was removed by spinning in a centrifuge for 5 min at 1,700 
g.  The supernatant was partially evaporated in a Genevac vacuum centrifuge for 
2 hr.  To the remaining mixture was added 0.25 mL neat formic acid, 0.25 mL 
CH3CN, and water to a final volume of 25 mL. This mixture was spun in a 
centrifuge at 40,000 g for 30 min.  The clarified supernatant was applied to an 
HPLC column (Polaris C18, 4.6 x 250 mm; 5µ particle size) through a Jasco 
HPLC pump at a rate of 0.8 mL/min.  After the entire sample was applied, an 
additional ~5 mL of mobile phase (0.1% formic acid containing 1% CH3CN) was 
pumped through the system.  The column was moved to a Thermo LTQ HPLC-
MS system containing a photodiode array detector and a mobile phase gradient 
was applied to elute material of interest.  The mobile phase was comprised of 
0.1% formic acid in water and CH3CN and was run at a flow rate of 0.8 mL/min.  
The gradient began at a composition of 2%B for 5 min followed by a linear 
gradient to 25%B at 70 min.  The eluent passed through the photodiode array 
detector scanning from 200-400 nm and then to a splitter (ratio was 
approximately 15:1) with the larger portion going to a CTC Leaptec fraction 
collector (CTC, Cary, NC).  Fractions were collected every 20 sec. The 
remainder was introduced into the mass spectrometer operated in the positive 
ion mode.  The fractions proposed to contain the hydroxy metabolites of interest 
were analyzed for identity and purity on a Thermo Orbitrap Elite UHPLC-UV-MS 
system containing an Acquity column (HSS T3 C18, 2.1 x 100 mm, 1.7 µm 
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particle size) using the mobile phases described above at a flow rate of 0.4 
mL/min and an injection volume of 5 µL.  The composition began at 5% solvent B 
for 0.5 min followed by a gradient to 35% solvent B at 8 min, a second gradient to 
95% solvent B at 10 min, and re-equilibration to initial conditions. Fractions 
containing single peaks by UV and the desired protonated molecular ions were 
combined and evaporated by vacuum centrifugation for analysis by NMR 
spectroscopy. Later, the fraction was reconstituted with 100 µL of DMSO-d6 prior 
to NMR analysis. NMR spectra were recorded on a Bruker Avance 600 MHz 
instrument (Bruker BioSpin Corporation, Billerica, MA). The 1H, and 2D NMR (1H 
COSY, HMBC, and HSQC) analyses were carried out in DMSO solutions of 
analyte. 
 
Enzyme Kinetic Studies 
The formation of major hydroxy metabolite in rAOX and HLC was studied 
to determine the enzyme kinetic parameters. Before the assessment of the 
enzyme kinetics, protein concentration and incubation time for the kinetic studies 
were evaluated to ensure the linearity of major hydroxy metabolite formation with 
respect to protein concentration and time. It was also seen that substrate 
utilization during the reaction was less than 10%. 
rAOX incubations 
PF-5190457 (0.5-125 µM) was incubated with rAOX (0.090 mg/mL) in 100 
mM potassium phosphate buffer. The incubations were conducted at 37°C in 
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shaking water bath. The incubation mixture volume was 50 µL and all incubation 
samples were in triplicate. The reactions were terminated after 120 min using ice-
cold methanol containing 2.5 ng/mL tacrine as IS.  
Screening of allopurinol and oxypurinol in HLC.  
The human livers utilized in this study were obtained from Sekisui 
XenoTech LLC which is typically retrieved from brain dead individuals for organ 
transplantation purpose but could not be transplanted. As such, the livers were 
perfused with the University of Wisconsin Cold Storage Solution (UW) containing 
allopurinol.  However, it is known that allopurinol and its primary metabolite 
oxypurinol to be potent inhibitors of xanthine oxidase (XO) activity (Barr et al., 
2014).  
To detect the presence the XO inhibitors, HLC (n=104) were tested for the 
presence of allopurinol and oxypurinol using the same LC-MS/MS 
instrumentation and mobile phases as described earlier in HLC and HLM 
analysis. The flow rate was 0.3 mL/min, the column was equilibrated at initial 
conditions of 90% solvent A for 1.2 min and then to 10% at 2 min. Over the next 
minute, solvent A was increased to 90% and then kept constant for a re-
equilibration time for 3 min. The total chromatographic run time was 3 min per 
sample. The multiple reaction monitoring (MRM) transitions used for allopurinol 
and oxypurinol detection were 137.1/110.1 and 153.1/136.1 respectively. 
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HLC incubations 
Kinetic parameters for the formation of the major hydroxy metabolite from 
PF-5190457 was determined by incubating the drug in pooled, allopurinol and 
oxypurinol free, HLC. The optimized total protein concentration and incubation 
times in HLC was 0.1 mg/mL and 5 min, respectively. PF-5190457 (0.05–100 
μM) with HLC in a total volume of 50 µL of 100 mM potassium phosphate buffer 
(pH-7.4) were incubated at 37°C in duplicate. The final concentration of methanol 
in the incubations was less than 0.25%. The reaction was initiated by the addition 
of cytosol. Incubations (50 µL) were terminated by protein precipitation with the 
addition of methanol (200 µL) containing the 2.5 ng/mL IS. 
LC-MS/MS analysis for kinetic studies 
 All the samples from rAOX and HLC were centrifuged for 5 min at 10,000 
rpm. The supernatants were removed and analyzed. The parent, metabolite and 
IS were monitored using Acquity UPLC system (Waters Corp., Milford, MA, 
USA) coupled to Xevo TQ-MS (Waters Corp., Milford, MA, USA). The analytes 
were separated using an aquity UPLC BEH C18 (2.1 x 50 mm, 1.7 µm particle 
size, 130Ǻ pore size) analytical column with an Acquity UPLC BEH C18 
VanGuard pre-column (2.1 x 5 mm, 130Ǻ). Mobile phase solution A consisted of 
water: methanol 95/5 % (v/v) and mobile phase solution B consisted of methanol 
(100%). Formic acid (0.1%) was added to both the mobile phase solutions. The 
flow rate was 0.25 mL/min with a 10.30 min run time. The column temperature 
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was maintained at 40°C. The gradient consisted of 2% methanol for 2 min, 
increased to 35% for 2.0 - 7.30 min, further increased to 95% methanol till 8 min 
and held until 8.30 min before returning to initial conditions to equilibrate with a 
total run time of 10.30 min. Mass spectral analysis and quantification was carried 
out using MRM on a positive electrospray ionization mode with the following 
parameters: desolvation temperature of 350°C, desolvation gas flow 650 L/h, 
capillary voltage 3.50 kV and cone voltage 20 V. The optimized settings of mass 
spectrometer voltage and the retention time (Rt) for the analytes and IS with 
quantifier and qualifier fragments are summarized in Table 1. Data acquisition 
and processing were performed using MassLynx™ software (V 4.1) and 
TargetLynx™ tool respectively. Retention times for hydroxy metabolite and 
internal standard were 4.4 and 5.1 min, respectively. Quantitation was done 
using a hydroxy metabolite standard curve ranging from 0.1-1 µM. The 
calibration standards were within ± 15% of nominal values. 
 
Inhibition Studies 
Incubation of PF-5190457 in HLC (with AO and XO inhibitors) 
PF-5190457 (25 µM) was incubated with pooled allopurinol/oxypurinol free 
HLC (n=9) in a total volume of 50 µL of 100 mM potassium phosphate buffer (pH-
7.4) in the presence and absence of inhibitors. Incubation conditions were similar 
to previous HLC kinetic experiments. To identify the enzymes involved in the  
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formation major hydroxy metabolite, HLC was incubated with and without AO 
inhibitor (raloxifene 0.005-50 µM), and XO inhibitor (febuxostat 0.001-50 µM). 
The reactions were terminated at 5 min using methanol containing 2.5 ng/mL 
tacrine as internal standard (IS). The samples were analyzed using LC-MS/MS 
as described under enzyme kinetic studies. 
 
Data Analysis 
Estimations of the maximum rate of major hydroxy metabolite formation 
(Vmax) and the Michaelis-Menten constant (Km) were performed using nonlinear 
regression analysis within GraphPad Prism (GraphPad Software Inc., La Jolla, 
CA) using the Michaelis-Menten equation given below.  
V = (Vmax*S)/(Km+S) 
The apparent in vitro intrinsic clearance (Clint) was calculated as Vmax/Km. 
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Results 
Characterization of PF-5190457 Metabolites in Human Plasma 
The circulating metabolites of PF-5190457 were determined in the plasma 
of human subjects who were administered PF-5190457 orally in a phase 1b 
clinical study (Fig. 2). Two peaks with protonated molecular ions of 16 mass units 
greater than PF-5190457 were observed (m/z 529.2382), indicating the addition 
of oxygen. Fragment ions of the hydroxyl metabolite that had a greater ion 
abundance included m/z 351.2179, 305.1430, and 225.1022 (Fig. 3) which is 
indicative of an oxidative biotransformation on the indenyl-pyrimidine portion of 
the molecule. Additional metabolites proposed as glucuronide and hydroxy 
glucuronide conjugates (m/z 689 and 705) were detected at apparent lower 
levels in the plasma. 
 
In Vitro Biotransformation of PF-5190457  
HLM and HLC 
Preliminary experiments conducted in the subcellular fractions of the 
human liver generated the major hydroxyl metabolite in HLC without the addition 
of cofactors. The metabolite formed in HLC increased with incubation time, 
concentration of substrate, and concentration of cytosol. The hydroxy metabolite 
was detected in HLC as the protonated molecular ion [M + H]+ at m/z 529. 
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Fragmentation of this ion produced fragments at m/z 225 and 351 (Fig. 4). This 
metabolite was not observed in HLM supplemented with NADPH. 
Hepatocytes  
The formation of hydroxyl metabolites of PF-5190457 was observed in 
human hepatocytes as shown in the chromatogram (Fig. 5). The traces were 
extracted ion chromatograms of m/z 529.2376 (5 ppm tolerance) representing 
the protonated molecular ion of a hydroxylated metabolite. The addition of ABT, a 
broad-spectrum P450 inactivator inhibited the formation of the apparent minor 
metabolites at Rt 4.12, 4.62, and 5.57 min and had no effect on the metabolite 
eluting at Rt 3.98 min suggesting that CYP mediated metabolism for the minor 
metabolites and not the major metabolite. It was also observed that addition of 
hydralazine inhibited formation of the metabolite at Rt 3.97 min indicating that AO 
could be responsible for the generation of this metabolite. 
Incubations in liver cytosol from various species 
The formation of hydroxy metabolite (513+13) was observed in cytosolic 
incubations of PF-5190457 in mouse (male and female), rat (male), monkey 
(female) indicating the metabolism to be independent of NADPH (Fig. 6). The 
hydroxy metabolite formed in cytosol of various species had similar retention time 
to that of the metabolite formed in HLC.  
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NMR Analysis 
Characterization of biosynthesized hydroxy metabolite by NMR analysis 
demonstrated that the site of hydroxylation was on the carbon between the 
nitrogen on the 4-methylpyrimidine moiety (Fig. 7). 1H COSY, HMQC, and HMBC 
spectra were obtained to support the hydroxylation of pyrimidine moiety 
(Supplemental data Fig. 2, 3 (a) and (b)). 
 
Enzyme Kinetic Analysis 
The HLC that were free (n=9) of allopurinol and oxypurinol were pooled 
together for further kinetic and inhibition experiments. The kinetics for the 
formation of major hydroxy metabolite from PF-5190457 was determined by 
incubating in rAOX and HLC. Representative Michaelis-Menten kinetic plots in 
rAOX and HLC are depicted in Fig. 8 and Fig. 9. Substrate inhibition kinetics at 
higher concentration of substrate was observed for rAOX incubations. The Km 
and Vmax values for the formation of hydroxy metabolite in rAOX and HLC were 
found to be 6.9 μM and 0.35 nmol/min/mg protein and 42 μM and 0.12 
nmol/min/mg protein respectively. The Clint in rAOX and HLC were 0.05 and 
0.002 mL/min/mg protein respectively.  
 
Biotransformation of PF-5190457 is mediated by AO and XO 
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The effect of AO (raloxifene) and XO (febuxostat) inhibitors on the 
metabolism of PF-5190457 was investigated. There was considerable (>75%) 
but not complete inhibition of formation of the major hydroxy metabolite with 50 
µM raloxifene (Fig. 10a). The extent of inhibition with febuxostat was greater than 
50% at 1 µM (Fig. 10b) and further increases in inhibitor concentration did not 
inhibit the formation of metabolite. 
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Discussion 
Characterization of circulating metabolites from patients orally 
administered with PF-5190457 revealed the biotransformation pathways for this 
ghrelin receptor inverse agonist. The primary route of metabolism observed in 
humans was hydroxylation yielding a major hydroxy metabolite of PF-5190457).  
In vitro experiments showed that this metabolite was generated in human liver 
cytosol. The metabolite profiling of major circulating metabolite (m/z 529a) in 
human plasma and the metabolite formed in HLC (m/z 529) showed similar 
MS/MS fragmentation pattern (m/z 225, m/z 351) suggesting hydroxylation on 
the pyrimidine ring yielding strong correlation between in vivo and in vitro data.  
Results from these experiments suggest that primary biotransformation process 
is non-NADPH-dependent metabolism in HLC leading to the formation of a 
hydoxy pyrimidine metabolite. The formation of the metabolite by NADPH 
independent process in HLC and the site of hydroxylation position on the PF-
5190457 confirmed from NMR analysis suggested the involvement of 
molybdenum co-factor containing enzymes like AO and/or XO mediated 
biotransformation. The position of hydroxylation on the pyrimidine ring between 
the two nitrogen atoms suggests nucleophilic attack via AO and/or XO enzymes 
in the metabolism of the drug (Krenitsky et al., 1972; Beedham, 1985; Kitamura 
et al., 2006).  In contrast to electrophillic oxidation by CYP450 enzymes, both AO 
and XO enzymes display nucleophilic attack on carbon atom which is electron 
deficient or carbon adjacent to N-heterocycle (eg. purines, pyrimidines and 
pteridines) resulting in the formation of distinct metabolites (Krenitsky et al., 
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1972). Furthermore, the use of inhibitors indicated contribution of both AO and 
XO enzymes to the formation of hydoxy pyrimidine metabolite of PF-5190457. 
The data also suggest AO as a dominant enzyme in comparison to XO in the 
biotransformation of PF-5190457.  
AO and XO enzymes belong to a family of molybdo-flavoenzymes and 
have a high level of similarity between their amino acid sequence homology 
(Beedham, 1987; Terao et al., 2000; Hille, 2005). XO can exists as two 
interconvertible forms as xanthine oxidase and xanthine dehydrogenase unlike 
AO (Della Corte et al., 1969). AO was found to be one of the highly abundant 
enzymes in HLC and the expression of AO was greater in comparison to XO in 
human liver (Nishimura and Naito, 2006; Sodhi et al., 2015).  Physiological 
relevance of AO is still not known but XO plays an important role in catalyzing 
hypoxanthine to xanthine and later to uric acid (Beedham, 1985; Kitamura et al., 
2006). Both the enzymes differ in substrate and inhibitors specificity.  Increasing 
number of substrates in the past few decades have been identified to be 
catalyzed by the two enzymes especially involving AO which also has broader 
substrate specificity in comparison to XO (O'Connor et al., 2006; Pryde et al., 
2010; Sanoh et al., 2015; Battelli et al., 2016). There are only few substrates 
which show biotransformation by both the enzymes like 6-deoxyclovir, 6-
thioxanthine, and recently VU0409106 a lead compound for childhood 
developmental disorders (Krenitsky et al., 1984; Morrison et al., 2012; Choughule 
et al., 2014). Though some overlap exists between the substrates, there has 
been various panel of chemical inhibitors identified specifically for AO and XO 
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inhibitors including raloxifene (Obach, 2004), hydralazine (Strelevitz et al., 2012), 
allopurinol (Panoutsopoulos et al., 2004) and febuxostat (Weidert et al., 2014). 
Allopurinol has been widely used as a known XO inhibitor but recently it was 
identified that febuxostat is a more potent inhibitor of XO than allopurinol (Malik 
et al., 2011). There are not any important clinical drug-drug interactions 
associated with inhibition of AO but as growth in new chemical entities 
metabolized by AO is increasing, there could arise a need to characterize in 
drug-drug interaction potential at AO level (Obach, 2004; Pryde et al., 2010).  It is 
a challenge to capture the drug interactions associated with these enzymes 
especially for AO enzyme in animal models as there exist species differences for 
expression and activity along with disparity with gender and strain (Itoh, 2009; 
Crouch et al., 2017; Mao et al., 2017). 
Both potent XO inhibitors, allopurinol and febuxostat are clinically used for 
treatment of chronic gout and hyperuricemia.  This condition is also present in 
disease states like metabolic syndrome, diabetes, chronic liver disease and 
cardiovascular disease (Hu and Tomlinson, 2008; George and Minter, 2017) 
some of which are target population for PF-5190457. There have been drug-drug 
interactions reported in man through the inhibition of XO substrates. For 
example, in one clinical study, allopurinol significantly inhibited 6-mercaptopurine 
which is a substrate for XO when administered orally and there was significant 
increase in peak plasma concentration and area under the curve of 6-
mercaptopurine in patients with acute lymphoblastic leukemia (Zimm et al., 
1983).  
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Inter-individual variability between donors has been observed in in vitro 
studies for hepatic AO and XO activity (Guerciolini et al., 1991; Al-Salmy, 2001; 
Hutzler et al., 2014). However, single nucleotide polymorphisms in the AO and 
XO genes has not been extensively studied in various populations (Levartovsky 
et al., 2000; Gok et al., 2003; Hutzler et al., 2014). Genetic polymorphism of AO 
gene was studied in an Italian study and the presence of both fast and poor 
metabolizers was observed (Hartmann et al., 2012). Moreover, two in vitro 
studies showed genetic variation in the XO gene could be responsible in 
individual variations in XO activity (Kudo et al., 2008; Kudo et al., 2010).  A 
recent study in European population suggests that XO variants had influence on 
uric acid production since XO also catalyzes uric acid production (Scheepers et 
al., 2016). 
Both in vitro and in vivo studies recognized the hydroxy pyrimidine 
metabolite as the major metabolite of PF-5190457. The findings presented here 
shows that both AO and XO contribute to the metabolism of PF-5190457 
resulting in the formation of a major circulating metabolite. The study also 
emphasizes the importance of these non-CYP enzymes in the drug metabolism 
during the early stages of drug development. The kinetics of PF-5190457 in 
rAOX and HLC gave an impression on the sub saturation concentrations in the 
allopurinol free livers. The data and the experimental conditions could be used in 
the future to investigate the Clint to study the effect of various factors like age, 
gender, smoking, alcohol use or disease states to improve the clinical 
pharmacokinetics and efficacy of the drug in that respective population. 
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The pharmacokinetic profile of the PF-5190457 and its major hydroxy 
metabolite has been investigated in plasma samples obtained from human 
subjects during the phase 1b study which is described elsewhere (Manuscript 
IV). It is important to identify the other metabolic pathways and route of 
elimination of PF-5190457 in the context of a mass balance study. 
Conflict of interest 
 
Dr. Obach is an employee of Pfizer Pharmaceuticals.  Other authors declare no 
potential conflict of interest with any commercial entity whose products were 
used in the study. 
 
Acknowledgements 
The financial support of Grant #UH3TR000963 from National Institutes of Health 
is gratefully acknowledged.  
63 
 
References 
Al-Salmy HS (2001) Individual variation in hepatic aldehyde oxidase activity. 
IUBMB Life 51:249-253. 
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya 
M, Niijima A, Fujino MA, and Kasuga M (2001) Ghrelin is an appetite-stimulatory 
signal from stomach with structural resemblance to motilin. Gastroenterology 
120:337-345. 
Barr JT, Choughule KV, Nepal S, Wong T, Chaudhry AS, Joswig-Jones CA, 
Zientek M, Strom SC, Schuetz EG, Thummel KE, and Jones JP (2014) Why do 
most human liver cytosol preparations lack xanthine oxidase activity? Drug 
Metab Dispos 42:695-699. 
Battelli MG, Polito L, Bortolotti M, and Bolognesi A (2016) Xanthine 
Oxidoreductase in Drug Metabolism: Beyond a Role as a Detoxifying Enzyme. 
Curr Med Chem 23:4027-4036. 
Beedham C (1985) Molybdenum hydroxylases as drug-metabolizing enzymes. 
Drug Metab Rev 16:119-156. 
Beedham C (1987) Molybdenum hydroxylases: biological distribution and 
substrate-inhibitor specificity. Prog Med Chem 24:85-127. 
Bhattacharya SK, Andrews K, Beveridge R, Cameron KO, Chen C, Dunn M, 
Fernando D, Gao H, Hepworth D, Jackson VM, Khot V, Kong J, Kosa RE, 
Lapham K, Loria PM, Londregan AT, McClure KF, Orr ST, Patel J, Rose C, 
Saenz J, Stock IA, Storer G, VanVolkenburg M, Vrieze D, Wang G, Xiao J, and 
Zhang Y (2014) Discovery of PF-5190457, a Potent, Selective, and Orally 
Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate. ACS Med 
Chem Lett 5:474-479. 
Choughule KV, Barnaba C, Joswig-Jones CA, and Jones JP (2014) In vitro 
oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of 
the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine 
dehydrogenase. Drug Metab Dispos 42:1334-1340. 
Crouch RD, Blobaum AL, Felts AS, Conn PJ, and Lindsley CW (2017) Species-
Specific Involvement of Aldehyde Oxidase and Xanthine Oxidase in the 
Metabolism of the Pyrimidine-Containing mGlu5-Negative Allosteric Modulator 
VU0424238 (Auglurant). Drug Metab Dispos 45:1245-1259. 
Della Corte E, Gozzetti G, Novello F, and Stirpe F (1969) Properties of the 
xanthine oxidase from human liver. Biochim Biophys Acta 191:164-166. 
Denney WS, Sonnenberg GE, Carvajal-Gonzalez S, Tuthill T, and Jackson VM 
(2017) Pharmacokinetics and pharmacodynamics of PF-05190457: The first oral 
ghrelin receptor inverse agonist to be profiled in healthy subjects. Br J Clin 
Pharmacol 83:326-338. 
George C and Minter DA (2017) Hyperuricemia, in: StatPearls, Treasure Island 
(FL). 
Ghareeb M, Leggio L, El-Kattan A, and Akhlaghi F (2015) Development and 
validation of an UPLC-MS/MS assay for quantitative analysis of the ghrelin 
receptor inverse agonist PF-5190457 in human or rat plasma and rat brain. Anal 
Bioanal Chem 407:5603-5613. 
64 
 
Gok F, Ichida K, and Topaloglu R (2003) Mutational analysis of the xanthine 
dehydrogenase gene in a Turkish family with autosomal recessive classical 
xanthinuria. Nephrol Dial Transplant 18:2278-2283. 
Guerciolini R, Szumlanski C, and Weinshilboum RM (1991) Human liver xanthine 
oxidase: nature and extent of individual variation. Clin Pharmacol Ther 50:663-
672. 
Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, and 
Leimkuhler S (2012) The impact of single nucleotide polymorphisms on human 
aldehyde oxidase. Drug Metab Dispos 40:856-864. 
Hille R (2005) Molybdenum-containing hydroxylases. Arch Biochem Biophys 
433:107-116. 
Hu M and Tomlinson B (2008) Febuxostat in the management of hyperuricemia 
and chronic gout: a review. Ther Clin Risk Manag 4:1209-1220. 
Hutzler JM, Yang YS, Brown C, Heyward S, and Moeller T (2014) Aldehyde 
oxidase activity in donor-matched fresh and cryopreserved human hepatocytes 
and assessment of variability in 75 donors. Drug Metab Dispos 42:1090-1097. 
Inui A, Asakawa A, Bowers CY, Mantovani G, Laviano A, Meguid MM, and 
Fujimiya M (2004) Ghrelin, appetite, and gastric motility: the emerging role of the 
stomach as an endocrine organ. FASEB J 18:439-456. 
Itoh K (2009) [Individual and strain differences of aldehyde oxidase in the rat]. 
Yakugaku Zasshi 129:1487-1493. 
Jamwal R, Barlock BJ, Adusumalli S, Ogasawara K, Simons BL, and Akhlaghi F 
(2017) Multiplex and Label-Free Relative Quantification Approach for Studying 
Protein Abundance of Drug Metabolizing Enzymes in Human Liver Microsomes 
Using SWATH-MS. J Proteome Res. 
Kitamura S, Sugihara K, and Ohta S (2006) Drug-metabolizing ability of 
molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98. 
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, and Kangawa K (1999) 
Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 
402:656-660. 
Kong J, Chuddy J, Stock IA, Loria PM, Straub SV, Vage C, Cameron KO, 
Bhattacharya SK, Lapham K, McClure KF, Zhang Y, and Jackson VM (2016) 
Pharmacological characterization of the first in class clinical candidate PF-
05190457: a selective ghrelin receptor competitive antagonist with inverse 
agonism that increases vagal afferent firing and glucose-dependent insulin 
secretion ex vivo. Br J Pharmacol 173:1452-1464. 
Korbonits M, Goldstone AP, Gueorguiev M, and Grossman AB (2004) Ghrelin--a 
hormone with multiple functions. Front Neuroendocrinol 25:27-68. 
Krenitsky TA, Hall WW, de Miranda P, Beauchamp LM, Schaeffer HJ, and 
Whiteman PD (1984) 6-Deoxyacyclovir: a xanthine oxidase-activated prodrug of 
acyclovir. Proc Natl Acad Sci U S A 81:3209-3213. 
Krenitsky TA, Neil SM, Elion GB, and Hitchings GH (1972) A comparison of the 
specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 
150:585-599. 
65 
 
Kudo M, Moteki T, Sasaki T, Konno Y, Ujiie S, Onose A, Mizugaki M, Ishikawa 
M, and Hiratsuka M (2008) Functional characterization of human xanthine 
oxidase allelic variants. Pharmacogenet Genomics 18:243-251. 
Kudo M, Sasaki T, Ishikawa M, Hirasawa N, and Hiratsuka M (2010) Functional 
characterization of genetic polymorphisms identified in the promoter region of the 
xanthine oxidase gene. Drug Metab Pharmacokinet 25:599-604. 
Kumar GN and Surapaneni S (2001) Role of drug metabolism in drug discovery 
and development. Med Res Rev 21:397-411. 
Leggio L, Addolorato G, Cippitelli A, Jerlhag E, Kampov-Polevoy AB, and Swift 
RM (2011) Role of feeding-related pathways in alcohol dependence: A focus on 
sweet preference, NPY, and ghrelin. Alcohol Clin Exp Res 35:194-202. 
Leggio L, Zywiak WH, Fricchione SR, Edwards SM, de la Monte SM, Swift RM, 
and Kenna GA (2014) Intravenous ghrelin administration increases alcohol 
craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol 
Psychiatry 76:734-741. 
Levartovsky D, Lagziel A, Sperling O, Liberman U, Yaron M, Hosoya T, Ichida K, 
and Peretz H (2000) XDH gene mutation is the underlying cause of classical 
xanthinuria: a second report. Kidney Int 57:2215-2220. 
Lin JH and Lu AY (1997) Role of pharmacokinetics and metabolism in drug 
discovery and development. Pharmacol Rev 49:403-449. 
Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, Tarpey MM, and Kelley 
EE (2011) Febuxostat inhibition of endothelial-bound XO: implications for 
targeting vascular ROS production. Free Radic Biol Med 51:179-184. 
Mao Z, Wu Y, Li Q, Wang X, Liu Y, and Di X (2017) Aldehyde oxidase-dependent 
species difference in hepatic metabolism of fasudil to hydroxyfasudil. 
Xenobiotica:1-8. 
Morrison RD, Blobaum AL, Byers FW, Santomango TS, Bridges TM, Stec D, 
Brewer KA, Sanchez-Ponce R, Corlew MM, Rush R, Felts AS, Manka J, Bates 
BS, Venable DF, Rodriguez AL, Jones CK, Niswender CM, Conn PJ, Lindsley 
CW, Emmitte KA, and Daniels JS (2012) The role of aldehyde oxidase and 
xanthine oxidase in the biotransformation of a novel negative allosteric modulator 
of metabotropic glutamate receptor subtype 5. Drug Metab Dispos 40:1834-
1845. 
Nagaya N, Itoh T, Murakami S, Oya H, Uematsu M, Miyatake K, and Kangawa K 
(2005) Treatment of cachexia with ghrelin in patients with COPD. Chest 
128:1187-1193. 
Nagaya N, Moriya J, Yasumura Y, Uematsu M, Ono F, Shimizu W, Ueno K, 
Kitakaze M, Miyatake K, and Kangawa K (2004) Effects of ghrelin administration 
on left ventricular function, exercise capacity, and muscle wasting in patients with 
chronic heart failure. Circulation 110:3674-3679. 
Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei 
MA, Coombes RC, and Bloom SR (2004) Ghrelin increases energy intake in 
cancer patients with impaired appetite: acute, randomized, placebo-controlled 
trial. J Clin Endocrinol Metab 89:2832-2836. 
66 
 
Nishimura M and Naito S (2006) Tissue-specific mRNA expression profiles of 
human phase I metabolizing enzymes except for cytochrome P450 and phase II 
metabolizing enzymes. Drug Metab Pharmacokinet 21:357-374. 
O'Connor D, Jones P, Chambers MS, Maxey R, Szekeres HJ, Szeto N, Scott-
Stevens P, Macleod AM, Braun M, and Cato B (2006) Aldehyde oxidase and its 
contribution to the metabolism of a structurally novel, functionally selective 
GABAA alpha5-subtype inverse agonist. Xenobiotica 36:315-330. 
Obach RS (2004) Potent inhibition of human liver aldehyde oxidase by 
raloxifene. Drug Metab Dispos 32:89-97. 
Ortiz de Montellano PR and Mathews JM (1981) Autocatalytic alkylation of the 
cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of 
an NN-bridged benzyne-protoporphyrin IX adduct. Biochem J 195:761-764. 
Panoutsopoulos GI, Kouretas D, and Beedham C (2004) Contribution of 
aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the 
oxidation of aromatic aldehydes. Chem Res Toxicol 17:1368-1376. 
Pryde DC, Dalvie D, Hu Q, Jones P, Obach RS, and Tran TD (2010) Aldehyde 
oxidase: an enzyme of emerging importance in drug discovery. J Med Chem 
53:8441-8460. 
Sanoh S, Tayama Y, Sugihara K, Kitamura S, and Ohta S (2015) Significance of 
aldehyde oxidase during drug development: Effects on drug metabolism, 
pharmacokinetics, toxicity, and efficacy. Drug Metab Pharmacokinet 30:52-63. 
Scheepers LE, Wei FF, Stolarz-Skrzypek K, Malyutina S, Tikhonoff V, Thijs L, 
Salvi E, Barlassina C, Filipovsky J, Casiglia E, Nikitin Y, Kawecka-Jaszcz K, 
Manunta P, Cusi D, Boonen A, Staessen JA, and Arts IC (2016) Xanthine 
oxidase gene variants and their association with blood pressure and incident 
hypertension: a population study. J Hypertens 34:2147-2154. 
Sodhi JK, Wong S, Kirkpatrick DS, Liu L, Khojasteh SC, Hop CE, Barr JT, Jones 
JP, and Halladay JS (2015) A novel reaction mediated by human aldehyde 
oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos 43:908-915. 
Strelevitz TJ, Orozco CC, and Obach RS (2012) Hydralazine as a selective 
probe inactivator of aldehyde oxidase in human hepatocytes: estimation of the 
contribution of aldehyde oxidase to metabolic clearance. Drug Metab Dispos 
40:1441-1448. 
Suchankova P, Steensland P, Fredriksson I, Engel JA, and Jerlhag E (2013) 
Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption 
and the alcohol deprivation effect in rats following long-term voluntary alcohol 
consumption. PLoS One 8:e71284. 
Terao M, Kurosaki M, Saltini G, Demontis S, Marini M, Salmona M, and Garattini 
E (2000) Cloning of the cDNAs coding for two novel molybdo-flavoproteins 
showing high similarity with aldehyde oxidase and xanthine oxidoreductase. J 
Biol Chem 275:30690-30700. 
Tong J, Prigeon RL, Davis HW, Bidlingmaier M, Kahn SE, Cummings DE, 
Tschop MH, and D'Alessio D (2010) Ghrelin suppresses glucose-stimulated 
insulin secretion and deteriorates glucose tolerance in healthy humans. Diabetes 
59:2145-2151. 
67 
 
Volkow ND, Wang GJ, Tomasi D, and Baler RD (2013) Obesity and addiction: 
neurobiological overlaps. Obes Rev 14:2-18. 
Weidert ER, Schoenborn SO, Cantu-Medellin N, Choughule KV, Jones JP, and 
Kelley EE (2014) Inhibition of xanthine oxidase by the aldehyde oxidase inhibitor 
raloxifene: implications for identifying molybdopterin nitrite reductases. Nitric 
Oxide 37:41-45. 
Yildiz BO, Suchard MA, Wong ML, McCann SM, and Licinio J (2004) Alterations 
in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. 
Proc Natl Acad Sci U S A 101:10434-10439. 
Zimm S, Collins JM, O'Neill D, Chabner BA, and Poplack DG (1983) Inhibition of 
first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine 
and allopurinol. Clin Pharmacol Ther 34:810-817. 
 
68 
 
Legend for Tables 
Table II-1. Mass spectrometry parameters for analytes and IS 
Compound 
Parent 
ion 
(m/z) 
Daughter 
Ion (m/z) 
Dwell 
(s) 
Cone 
(V) 
Collision 
energy 
(V) 
Retention 
Time 
(min) 
Parent 
drug (PF-
5190457) 
513 209, 335 0.025 30, 30 44, 16 5.6 
Major 
hydroxy 
metabolite 
529 225, 351 0.025 34, 32 40, 20 4.5 
Internal 
standard 
(tacrine) 
199 170, 143 0.025 46, 42 30, 36 5.9 
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Legend of Figures 
Fig. 1. Structure of PF-5190457 
Fig. 2. Metabolic profiles of pooled patient plasma samples at various sampling 
times (predose, early and late times) after administration of PF-5190457 
analyzed by HPLC-UV and HPLC-MS/MS (representative m/z of the detected 
metabolites). 
Fig. 3. Full scan and daughter ion scan of the major metabolite 529a detected at 
7:30 min in the pooled human plasma samples. 
Fig. 4. Representative mass spectra in HLC. (a) Experimental PF-5190457 
incubation sample in HLC (b) Blank cytosol without the addition of substrate 
Fig. 5. HPLC-MS traces for PF-5190457 incubated in pooled human hepatocytes 
Fig. 6. HPLC-MS traces for PF-5190457 incubated in liver cytosol various 
species. 
Fig. 7. 1H Proton NMR Spectra of hydroxy metabolite of PF-5190457 
Fig. 8. Representative kinetics for the metabolism of PF-5190457 to hydroxy 
metabolite in recombinant aldehyde oxidase incubations.  
Fig. 9. Representative kinetics for the metabolism of PF-5190457 to hydroxy 
metabolite in human liver cytosolic incubations.  
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Fig. 10. Hydroxy metabolite formation in the presence of inhibitors (% of control) 
at various concentrations of, (a) raloxifene and (b) febuxostat with 25 µM PF-
5190457 in human liver cytosolic incubations.  
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Fig. II-1. Structure of PF-5190457  
 
 
Fig. II-2. Metabolic profiles of pooled patient plasma samples at various sampling 
times (predose, early and late) after administration of PF-5190457 after HPLC-
UV and HPLC-MS/MS analysis (representative m/z of the detected metabolites). 
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Fig. II-3. Full scan and daughter scan of the major metabolite 529a detected at 
7:30 min in the pooled human plasma samples. 
  
 
Fig. II-4. Representative mass spectra in HLC. (a) Experimental PF-5190457 
incubation sample in HLC (b) Blank cytosol without the addition of substrate
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Fig. II-5. HPLC-MS Traces for PF-5190457 incubated in pooled human 
hepatocytes. Peaks at Rt of 4.12, 4.62, and 5.57 min (denoted with blue arrows) 
were sensitive to ABT. The peak eluting at 3.97 min (denoted with red arrows) 
was insensitive to ABT but was inhibited by hydralazine. 
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Fig. II-6. HPLC-MS Traces for PF-5190457 incubated in liver cytosol various 
species.  Peaks at Rt of 3.12 and 3.61 min represents hydroxylated metabolite 
(513+16) and parent drug respectively. 
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Fig.II-7. 1H Proton NMR Spectra of hydroxy metabolite of PF-5190457 
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Fig. II-8. Representative kinetics for the metabolism of PF-5190457 to hydroxy 
metabolite formation in recombinant aldehyde oxidase incubations. Increasing 
concentrations of PF-5190457 (0.52 – 125 μM) were incubated with recombinant 
aldehyde oxidase (0.090 mg/mL) for 120 min at 37°C. Formation rates of 
metabolite (nmol/min/mg protein) versus PF-5190457 concentration (μM) were 
best-fit using nonlinear-regression analysis. 
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Fig. II-9. Representative kinetics for the metabolism of PF-5190457 to hydroxy 
metabolite in human liver cytosolic incubations. Increasing concentrations of PF-
5190457 (1.5 – 400 μM) were incubated with human liver cytosolic samples (0.1 
mg/mL) for 5 min at 37°C. Formation rates of metabolite (nmol/min/mg protein) 
versus PF-5190457 concentration (μM) were best-fit using non-linear regression 
analysis 
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Fig. II-10. Hydroxy metabolite formation in the presence of inhibitors (% of 
control) at various concentrations of, (a) raloxifene and (b) febuxostat with 25 µM 
PF-5190457 in allopurinol free (n=9) pooled human liver cytosolic incubations.  
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Supplemental Data 
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Supplemental Fig II-1 Shows percentage of PF-5190457 hydroxy metabolite 
formed in the presence and absence of inhibitors at various concentrations of (a) 
hydralazine, (b) allopurinol; the incubations contained 25 µM PF-5190457 in 
allopurinol free (n=9) pooled human liver cytosolic fraction
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Supplemental Fig. II-2. COSY: Black Curves HMBC: Red Curves  
 
 
 
Supplemental Fig II-3a and b. COSY NMR Spectra and HSQC NMR Spectra of 
hydroxy metabolite supporting oxidation at pyrimidine moiety 
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Abstract 
The present study describes the use of a mass spectrometry based label-free 
quantification approach to estimate the expression of aldehyde oxidase protein 
(AOX1) and also, to study the impact of various demographic factors on this 
enzyme in liver cytosolic fractions in a well-characterized bank of human liver (n 
= 104). Trypsin was used to digest cytosolic fractions, and a faster (90 min) 
digestion method was aided by a pressure cycling technology. Tryptically 
digested peptides were separated on an Acquity UHPLC Peptide BEH C18 
column. The total run time was 60 min using a gradient method at a ﬂow rate of 
0.1 mL/min. The HLC samples were analyzed using two acquisition methods by 
data-dependent acquisition (DDA) and SWATH-MS (sequential windowed 
acquisition of all theoretical fragment ion mass spectra) mode on quadrupole-
time-of-ﬂight mass spectrometer (ESI-QTOFMS) operated in positive 
electrospray ionization mode. SWATH-MS data extracted using Skyline (targeted 
proteomics data extraction software) generated values for relative quantification 
while absolute protein of AOX1 was calculated by MaxQuant (identification and 
quantitative proteomics software) using total protein approach. We found that 
results from SWATH-MS based acquisition were comparable to traditional DDA 
method. The AOX1 levels quantified using MaxQuant was found to be in the 
range of 2 - 49 pmol/mg cytosolic protein (19.5 fold), which are well comparable 
to published reports on the expression of the enzyme. The effect of demographic 
factors such as age, gender, ethnicity, smoking, drug use, alcohol consumption 
and disease condition like diabetes and non alcoholic fatty liver disease (NAFLD) 
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on AOX1 protein in individual HLC were studied, but no significant association 
was found. The reasons for observed variability could be because of other 
underlying and unknown factors which show a need for further studies on the 
enzyme. 
 
Abbreviations  
AO aldehyde oxidase, AOX1 human aldehyde oxidase protein, DDA Data 
dependent acquisition, DIA Data independent acquisition, SWATH-MS 
Sequential windowed acquisition of all theoretical fragment ion mass spectra, XO 
Xanthine Oxidase 
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Introduction 
Aldehyde oxidase (AO), along with xanthine oxidase (XO), belongs to the family 
of molybdo-flavoenzyme or molybdenum co factor containing enzymes and does 
not require NADPH as a cofactor for oxidation (Beedham, 1985; Hille, 2005). 
Unlike XO which catalyzes uric acid, the physiological function of AO in not 
known yet (Kitamura et al., 2006). In the recent year, AO is gaining significance 
in drug discovery programs because of a consorted effort to reduce the 
contribution of cytochrome P450 (CYP450) mediated biotransformation to the 
elimination of new drugs, (Pryde et al., 2010; Rashidi and Soltani, 2017). The 
new drug molecules are designed to have nitrogens in their rings like purines 
pyrimidines and pteridines to enable aldehyde oxidase metabolism (Lepri et al., 
2017; Paragas et al., 2017). In contrast to electrophilic attack by CYP450 
enzymes, aldehyde oxidase follows nucleophilic attack using the oxygen from the 
water (Beedham, 1985; Garattini et al., 2003). Various isoforms AOX1, AOX3, 
AOX3L1, and AOX4, have been identified with species differences. The 
functionally active aldehyde oxidase that is expressed in the human liver cytosol 
as AOX1 along with two other pseudogenes AOX3 and AOX3L1 (Kurosaki et al., 
2013).  
While a limited number of studies are published assessing the AOX1 
levels in HLC, it is known that a significant degree of variability is associated with 
the expression of this enzyme (Barr et al., 2013; Fu et al., 2013). In one of the 
studies, the AOX1 levels reported in three batches of pooled HLC was found to  
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be between 2 - 40 pmol/mg (20 fold) (Barr et al., 2013). The other study 
assessed the levels in 20 individual HLC donors and the results observed were 
much tighter ranging from 0.74 – 2.30 pmol/mg (~3 fold) (Fu et al., 2013). The 
variation between both the studies was observed to be about 17 – 28-fold. Both 
the studies mentioned above used the absolute method of quantification (MRM) 
using mass spectroscopy. 
The use of mass spectrometry is gaining popularity over traditional 
methods, such as Western blotting, enzyme-linked immunosorbent assays 
(ELISAs) and reverse-transcriptase polymerase chain reactions (RT-PCR) to 
monitor or quantify the expression of proteins (Han et al., 2008; Aebersold et al., 
2013). Label-Free relative quantiﬁcation approach for studying protein 
abundance of metabolizing enzymes in biological samples using mass 
spectrometry acquisition methods like data independent acquisition (DIA) and 
data dependent acquisition (DDA) (or information dependent acquisition) have 
been explored in the recent years (Hopfgartner et al., 2012). Our lab has recently 
published on using sequential windowed acquisition of all theoretical fragment 
ion mass spectra (SWATH-MS-MS), which is a DIA method, to study relative 
quantification of enzymes using a label free approach (Jamwal et al., 2017). 
In the present study, we used the DDA, and SWATH-MS to quantify the 
relative expression of AOX1 protein in the human liver cytosol. The main 
objective of the study was to quantify the AOX1 levels in a novel bank of human 
liver and to study the effect of various demographic factors on AO protein 
expression.
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Materials and Methods 
Chemical and Reagents. Trypsin digested β-galactosidase (E. coli), protein 
preparation kit, and L-1-p-Tosylamino-2-phenylethyl chloromethyl ketone 
(TPCK)-treated trypsin were purchased from Sciex (Framingham, MA). Mass 
spectrometry grade acetonitrile and formic acid were from ThermoFisher 
Scientiﬁc (Waltham, MA). Acquity UHPLC Peptide BEH C18 analytical column 
and VanGuard precolumn were from Waters Corp. (Milford, MA).  
Human liver bank. 
Human liver tissue (N=104) was purchased from Sekisui XenoTech LLC 
(Kansas City, KS). The livers were well characterized for age, gender, ethnicity, 
the cause of death, cold ischemia time, liver and body weight, smoking, alcohol 
consumption, diabetes and NAFLD. The information was available for ≥95% of 
the samples.  
HLC Preparation and Digestion.  
Preparation of HLC and digestion of the samples was performed as 
described previously (Jamwal et al., 2017). Brieﬂy, human liver samples were 
homogenized using a bead homogenizer (Bead Ruptor 24, Omni International, 
Kennesaw, GA). Ultracentrifugation was done to separate microsomes and 
cytosol. The cytosolic fraction thus obtained was stored in -80°c for future use. 
Cytosolic protein concentration was estimated using a bicinchoninic acid method 
(Pierce-Fisher, Rockford, IL) with bovine serum albumin as a standard. The  
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samples were diluted to 2.5 mg/mL in phosphate-buﬀered saline (pH 7.4) before 
protein digestion. The samples (150 µg of cytosolic protein) initially were 
denatured to disrupt the hydrogen and hydrophobic bonds of the proteins. 
Subsequent steps were to reduce the disulfide bonds of the proteins and 
addition of an alkylating agent to block the cysteine group in the samples. The 
digestion buffer was added to the cysteine blocked samples to maintain the 
optimum pH before digesting the samples. The proteins in the samples were 
digested with TPCK treated trypsin (1:20 enzyme/protein) in a Barocyler 
NEP2320− 45k (Pressure BioSciences Inc.) working on the principle of 
pressure aided digestion of proteins (pressure cycling technology-PCT). The 
optimized settings for temperature, cycles and pressure on the barocycler were 
50 °C for 90 cycles, 50 s at 35 kpsi and 10 s at ambient pressure for every 
cycle. Two technical replicates for each HLC sample were digested and 
analyzed by mass spectrometry. XTreme 200 pool of HLC sample was used as 
digestion control to monitor the batch-to-batch variation of protein digestion 
carried out in six batches. Mostly, 12 cytosolic samples and one XTreme 200 
pool of HLC as control sample were digested and run in every batch.  
LC-QTOF/MS Analysis.  
All the cytosolic digested samples were analyzed on a SCIEX 5600 
TripleTOF mass spectrometer equipped with a DuoSpray ion source (SCIEX, 
Concord, Canada) coupled to Acquity UHPLC HClass system (Waters Corp., 
Milford, MA, USA) which has a with a binary pump and a built-in column heater.  
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Mass spectral analysis was carried out using a positive electrospray ionization 
mode. Chromatography separation of peptides was accomplished within 11.30 
min using gradient elution method using an Acquity UHPLC Peptide BEH C18 
(2.1 × 150 mm2, 300 Å, 1.7 μm) analytical column. An Acquity VanGuard 
precolumn (2.1 × 5 mm 2, 300 Å, 1.7 μm) was used prior to the analytical 
column. The analytical column and autosampler temperature consisting digested 
samples were kept at 40 °C and 10°C, respectively. Mobile phase A consisted of 
98% water, 2% acetonitrile containing 0.1% formic acid and mobile phase B 98% 
acetonitrile, 2% water containing 0.1% formic acid. The mobile phase was 
delivered at 100 μL/min flow rate with a gradient method and total run time of 60 
min. The initial conditions of mobile phase composition are as follows: (98% A) 
was maintained for 3 min, 60% to 90% A from 3 to 48 min, and 20% A held till 52 
min and returned to initial conditions for equilibration. The amount of protein per 
injection on the column was 10 μg. In each batch, Trypsin-predigested beta-
galactosidase peptides were injected (∼30 pmol/injection) as quality control 
every 10 samples during the analysis to monitor mass calibration of the TOF 
detector and normalization of intensity during relative quantiﬁcation of AOX1 
protein (described below). The average intensity of the β-galactosidase peptide 
(APLDNDIGVSEATR) in a batch was used for data normalization of the 
respective batch of samples. 
DDA and SWATH-MS Data Acquisition Settings.  
Two acquisition methods, DDA and SWATH-MS method were used to  
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identify and quantify AOX1 protein. Analyst TF 1.7 was used to acquire data 
during the study (SCIEX, Framingham, MA). The detailed settings for source and 
compound parameters for both the acquisition methods are as described in 
previously published paper from our lab (Jamwal et al., 2017). The DDA 
experiments were performed in positive resolution mode over a mass range of 
m/z 350−950 with a charge state 2 to 4, and quadrupole resolution of 0.7 AMU 
were used for automated MS/MS analysis. Whereas, SWATH-MS-MS. based 
spectra were acquired for mass range m/z 400−900 Da with SWATH-MS window 
width of 25 m/z resulting in 20 overlapping mass windows per cycle.  
Raw Data Processing.  
Generation of spectral reference library 
The data files of HLC samples obtained from the DDA acquisition were 
analyzed using the database search engine ProteinPilot 5.0 (SCIEX; 
Framingham, MA, USA) The data were searched against the UniProt protein 
database. The search was specified using the following parameters in the 
Paragon method: sample type - identification; cysteine alkylation - MMTS; 
digestion - Trypsin; instrument - TripleTOF 5600, species - Homo sapiens; 
search effort -thorough and false discovery analysis - none.  
Method 1 Based on DIA-SWATH-MS MS and Skyline analysis.  
The spectral library generated from DDA ﬁles was uploaded in Skyline to 
identify AOX1 protein, and SWATH-MS data ﬁles were processed using the full  
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scan MS/MS ﬁltering at a resolution of 10000. Three unique AOX1 peptides were 
identified and curated for reproducible fragment ions. The total area of 
representative peptides for AOX1 protein was summed, and resulting intensity 
was normalized by total intensity of tryptic peptide of β-galactosidase. MultiQuant 
v 3.0 (SCIEX, Framingham, MA) was used to retrieve intensity for 
APLDNDIGVSEATR peptide and was subsequently used for normalization 
among diﬀerent batches as described above (Nakamura et al., 2016).  
Method 2 Based on DDA acquisition and MaxQuant analysis.  
The raw data files obtained from DDA data was analyzed for AOX1 using 
MaxQuant (Version 1.5) and was searched against UniProt human protein 
database at a false discovery rate (FDR) of 0.01. The absolute protein 
concentration was calculated from label-free quantification (LFQ) intensities 
using “Total Protein Approach”(Wisniewski and Rakus, 2014). 
Statistical analysis.  
Statistical analysis was performed with SPSS version 24 (IBM Analytics, 
Armonk, NY), and Prism® version 6 (GraphPad Software Inc., San Diego, CA) 
was used for graphs. Non-parametric Mann-Whitney U test  and Kruskal-Wallis 
test (2-tailed) were used to study the effect of three or more groups.  The 
correlation was studied using nonparametric Spearman correlation analysis. P 
<0.05 was considered significant for all the statistical tests and correlation 
analysis. 
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Results 
SWATH-MS based relative AOX1 levels 
Three unique peptides for AOX1 protein DILADVVQK, MIQVVSR, 
GTSTETVPNANISGGSVVADLNGLAVK and three fragment ions per peptide for 
the protein were identified. AOX1 levels from SWATH-MS files are represented 
after normalization Selected peptides for the relative quantiﬁcation of the AOX1 
protein were correlated with each other and also, with sum of the three peptides 
to validate the selection of peptides (Fig 1a and b). The correlation between the 
surrogate peptides (Spearman, r = 0.94, p<0.0001) was significant. Likewise, the 
correlation between one of the selected peptides (DILADVVQK) of AOX1 and 
sum of the peptides was significant (Spearman, r = 0.98, p<0.0001). Two other 
peptides had similar significant correlation (data not shown) generating 
confidence in the selection of peptides. 
DDA based absolute AOX1 levels 
The AOX1 levels in the cytosolic samples determined via total protein 
approach ranged from 2.46 – 49.02 pmol/mg cytosolic membrane protein. There 
was variability with about 19-fold difference between the samples. Fig 3 shows 
the distribution of AOX1 levels across various cytosolic samples. AOX1 levels 
obtained via MaxQuant were used to determine the effect of various 
demographic factors on the AO enzyme.  
Correlation between SWATH-MS and DDA based results 
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The correlation between the AOX1 levels measured via both the 
acquisition methods (DIA and DDA) was significant (Spearman, r = 0.72, 
p<0.0001) (Fig 3). The results indicate the reliability of either of the acquisition 
methods for determination of AOX1 levels. 
Effect of demographic factors on AOX1 levels.  
The effect of various factors like gender, age, weight, drug usage, 
ethnicity, smoking, alcohol consumption along with disease conditions like 
diabetes and NAFLD (non alcoholic fatty liver disease) was evaluated on AOX1 
levels.  
Cytosolic fatty acid synthase (FAS). FAS is observed to be a diagnostic marker 
for progression in NAFLD (Dorn et al., 2010). As the disease progresses, the 
FAS expression is expected to increase as seen in Fig 4. This enzyme was used 
as a positive control to determine the quality of data generated from mass 
spectroscopy.  
Effect of Ethnicity. 
The number of African American, Caucasian and Hispanic included in this 
study are as shown in Table 1.  In general, African Americans exhibited 
marginally higher AOX1 levels in comparison to Caucasian and Hispanic donors. 
However, no significant association (P>0.4) was observed between Ethnicity and 
AOX1 levels (Fig 5) (Table. 2). 
Effect of Alcohol. 
94 
 
Alcohol consumption in the liver donors were evaluated and scores were 
determined based on the drinking scale (None = 0, Safe = 1, Moderate = 2, 
Heavy = 3). The trend of AOX1 levels decreased with increase in alcohol 
consumption but not significant (P>0.4) (Fig 5) (Table.2)  
Effect of other demographic factors. 
Other demographic factors such as gender, age, weight, drug usage, 
smoking, along with disease conditions like diabetes and NAFLD (non alcoholic 
fatty liver disease) were not detected to have an impact on AOX1 levels based 
on our results. Table. 2 shows the effect of selected demographic factors on 
AOX1 with mean ±SE  
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Discussion 
The AOX1 levels measured in HLC were found to be variable in the present 
study. Cytosolic AOX1 levels in human livers were quantified using two different 
acquisition methods in mass spectroscopy. Our lab had initially developed a DIA 
method using SWATH-MS method to determine the relative protein levels of 
various drug metabolizing enzymes which was published recently (Jamwal et al., 
2017). DDA was used for identification of proteins in the earlier method (details in 
the method section). In due course, MaxQuant a quantitative proteomics 
software was utilized which allows both in identifying and quantifying the proteins 
of interest using the raw files generated from DDA (Cox et al., 2014). Both the 
acquisition methods (DIA and DDA) demonstrated good correlation with each 
other and reliability in using either method to quantify AOX1 protein. The 
cytosolic FAS protein (a marker for progression of NAFLD) assessment gave 
confidence in the reliability of the quantified protein levels using mass 
spectroscopy. The leverage of total protein approach in MaxQuant is that it gives 
accurate estimations of protein concentrations (Wisniewski et al., 2014). The 
absolute values of pmol of AOX1/mg of total cytosolic protein values generated 
from MaxQuant in the present study were comparable to other studies (Barr et 
al., 2013; Fu et al., 2013). The variation in our study was observed to be about 
25-fold (2 - 49 pmol/mg) in a novel bank of human livers. The AOX1 levels 
quantified were much closer to the results reported by Barr et al. in pooled HLC 
(Barr et al., 2013).  
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The expression of drug metabolizing enzymes can be influenced by many 
intrinsic and extrinsic factors (Rogers et al., 2002; Wilkinson, 2005; Fisher et al., 
2009; Merrell and Cherrington, 2011; Yang et al., 2013; He et al., 2015). Most 
importantly factors like genetic polymorphism (Meyer, 2004), epigenetic 
modifications like DNA methylation, histone protein modification or interaction 
with microRNAs (Chuang and Jones, 2007; Ingelman-Sundberg and Gomez, 
2010), and non genetic factors like age (Kinirons and O'Mahony, 2004), gender 
(Beierle et al., 1999) or disease state (Elbekai et al., 2004) can influence the 
expression of metabolizing enzymes. Pharmacokinetic variability in individuals 
can be largely explained by the above mentioned factors influencing the 
metabolizing enzymes and the knowledge of these factors is important to monitor 
the drug response (Lin, 2007).  
AOX1 is one of the highly abundant enzymes found in human liver 
(Beedham, 1987; Nishimura and Naito, 2006). Non alcoholic fatty liver disease 
(NAFLD) has demonstrated to influence the AOX1 levels. NAFLD is 
characterized by a spectrum of conditions ranging from simple steatosis, non-
alcoholic steatohepatitis with fibrosis progressing to cirrhosis (Targher et al., 
2008; Younossi et al., 2011). The rats fed with high-fat diet and primary 
hepatocytes loaded with palmitic acid showed an increase in AOX1 expression 
(Neumeier et al., 2006). It was observed that the primary hepatocytes for the 
study were isolated and cultured from tissue samples obtained were not from 
healthy subjects but from patients with liver tumors of colorectal cancer who were 
undergoing hepatectomy. The levels of AOX1 could also be influenced by 
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disease conditions like cancer. Certain phase I and II drug metabolizing 
enzymes, AOX1, CYP1B1, GSTM3 and GSTP1 gene and protein expression 
were found to be elevated in brain tumor specimens obtained from patients 
(n=77) undergoing primary resection (Stavrinou et al., 2015). Whereas, in the 
present study NAFLD did not have a significant impact on the AOX1 levels. 
In an in vitro study (Fu et al., 2013) poor correlation was observed 
between AOX1 activity and expression levels in HLC. Several demographic 
factors along with protein mis-folding, polymorphism and co-factor deficiency 
were suspected to be the reasons for observed poor correlation, but no clear 
conclusions were drawn owing to their small sample size (n=20). In the same 
study, chronic alcohol consumption in liver donors (n=2) decreased the AO 
activity significantly but not the AOX1 levels. The AOX1 levels in the present 
study were not altered significantly with increase in alcohol consumption. In other 
in vitro studies, considerable inter-individual variability in the AO metabolism has 
been observed using different substrates (Al-Salmy, 2001; Hutzler et al., 2014). It 
would have been beneficial if the studies had AOX1 levels measured to correlate 
with the observed activity and if any other demographic factors or post-
transitional modifications are influencing the activity of the protein. 
AO contains molybedenum and iron sulfur centers along with flavin 
adenine dinucleotide (Beedham, 1985).  Iron deficiency diet decreased the 
activity of AO in rats and increasing the iron reverted the activity to normal 
indicating iron to have a significant impact on AO enzyme (Mackler et al., 1978).  
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It is known that XO belongs to the same family as AO and is closely related 
enzyme to AO (Beedham, 1985). In a rat study, XO levels and activity were 
observed to be decreased with iron-depleted diet and increased when 
supplemented with iron (Ghio et al., 2002). Both these studies indicate iron could 
play an important role in modulating the AOX1 levels. 
Many other unknown factors could be the reason for observed variability in 
the AOX1 levels in our study. Recognizing the sources of variability could be 
challenging as there may be other underlying unknown epigenetic factors, 
disease state or dietary constituents influencing the enzyme. To the best of our 
knowledge, for the first time, the effect of demographic factors on AOX1 levels in 
a large number of human livers was studied.  
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Tables 
Table. III-1.  Detailed donor demographics 
N (total) 104 
Male, Female 49, 55 
Ethnicity# (n) C, AA, H 89, 10, 5 
Age1 (years) 50.2 ± 1.1 
Body-mass index1 (kg/m2) 31.4 ± 1.07 
Diabetes mellitus (no, yes) 51, 53 
Liver weight1 (kg) 1.59 ± 0.58 
Body weight1 (kg) 88.7 ± 2.84 
Smoking (no, yes) 46, 58 
Drug Usage (no, yes) 83, 21 
Alcohol consumption  
(Scale 0 -4) (no –heavy) 
42, 21, 19, 
10, 12 
NAFLD (Scale 0 - 2) 
(none - disease progression) 
41, 34, 29 
 
#C-Caucasian, AA-African-American, H-Hispanic; 1mean±SE. 
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Table. III-2.  Effect of demographic factors on AOX1 levels 
 
Factors Groups 
AOX1 
(pmol/mg)1 
Test P value 
Gender 
Male (n=55) 26.7 ± 1.2 
Mann-Whitney U  0.94 
Female (n=49) 26.9 ± 1.1 
Ethnicity#  
AA (n=10) 31 ± 0.9 
Kruskal Wallis  0.459 CC (n=89) 26.4 ± 3 
H (n=5) 25.2 ± 1 
Alcohol 
Consumption 
Scale  
0 (n=42) 27 ± 1.1 
Kruskal Wallis  0.466 
1 (n=21) 28.8 ± 2 
2 (n=19) 28.2 ± 2.4 
3 (n=10) 24.6 ± 1.8 
4 (n=12) 22.4 ± 2.5 
Smoking 
Yes (n=58) 26.7 ± 1.1 
Mann-Whitney U  0.587 
NO (n=46) 26.6 ± 1.3 
Diabetes 
Yes (n=53) 26.1 ± 1 
Mann-Whitney U  0.797 
NO (n=51) 27.7 ± 1.3 
NAFLD (Scale 
0-2) (none - 
progression 
of disease) 
0 (n=41) 27.7 ± 1.3 
Kruskal Wallis  0.254 1 (n=34) 25.9 ± 1.2 
2 (n=29) 26.5 ± 1.9 
#C-Caucasian, AA-African-American, H-Hispanic; 1mean±SE 
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Legend of Figures 
Fig. 1. Correlation plots 
Fig. 2. Correlation plot between DIA (SWATH-MS-MS) and DDA for AOX1 levels 
Fig. 3. Distribution of AOX1 levels across individual human liver cytosolic 
samples (n=104) 
Fig. 4. Cytosolic fatty acid synthase in NAFLD. 
Fig. 5. Effect of ethnicity on AOX1 levels 
Fig. 6. Effect of alcohol on AOX1 levels 
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Fig. III-1. Correlation plots (a) correlation between surrogate peptides of AOX1 
and (b) correlation between one of the unique peptide and sum of the peptides 
for AOX1 from SWATH-MS was considered significant (p<0.05) using correlation 
coefficient Spearman r. 
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Fig. III- 2. Correlation plot between DIA (SWATH-MS) and DDA for AOX1 levels. 
Correlation between two acquisition methods SWATH-MS and traditional DDA 
was considered significant (p<0.05) using correlation coefficient Spearman r 
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Fig. III-3. Distribution of AOX1 levels across individual human liver cytosolic 
samples (n=104). The AOX1 levels ranged from of 2-49 pmol/mg cytosolic 
protein (19.5 fold).  
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Fig. III-4. Cytosolic fatty acid synthase in non alcoholic fatty liver disease 
(NAFLD). Increase in cytosolic fatty acid synthase with progress in NAFLD was 
observed to be significant in HLC. NAFLD score (0 - 2) indicates none – 0, non 
alcoholic fatty liver – 1, progression to non-alcoholic steatohepatitis – 2. Column 
and error bars represent mean±SE. *P<0.05 reported from nonparametric 
Kruskal-Wallis test (2-sided). 
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Fig. III-5. Effect of ethnicity on AOX1 levels. Effect of ethnicity (AA – African 
American, CC – Caucasian, H – Hispanic) on AOX1 was observed to be not 
significant across the groups in HLC Column and error bars represent mean±SE. 
P >0.4 reported from nonparametric Kruskal-Wallis test (2-sided). 
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Fig. III-6. Effect of alcohol on AOX1 levels. Alcohol consumption had no 
significant effect on AOX1 levels in HLC. Alcohol consumption scale (0-4) 
indicated none to heavy drinking. (None = 0, Safe = 1, Moderate = 2, Heavy = 3). 
Column and error bars represent mean±SE. P >0.4 reported from nonparametric 
Kruskal-Wallis test (2-sided). 
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Clinical Pharmacokinetics of a Major Hydroxy Metabolite of PF-5190457, a 
Ghrelin Receptor Inverse Agonist- Evidence from In vivo and In vitro 
Studies 
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT  
 PF-5190457 is a ghrelin receptor inverse agonist. It has been proposed to 
treat alcohol use disorder and type 2 diabetes.  In phase 1 clinical studies, 
PF-5190457 was well tolerated in healthy volunteers and subjects in alcohol 
use disorder. 
 PF-5190457 is majorly metabolized by aldehyde oxidase enzyme to (add the 
name of AO metabolite) 
 Aldehyde oxidase is a cytosolic enzyme that displays high interindividual 
variability with different substrates 
WHAT THIS PAPER ADDS  
The manuscript, for the first time, reports the pharmacokinetics of PF-5190457 
and its major hydroxy metabolite in alcoholic subjects. The half-life of the 
metabolite was higher in comparison to the parent drug. The metabolism of PF-
5190457 was found to be variable across various human liver cytosolic fractions 
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AIM: To investigate the pharmacokinetics of PF-5190457 and its major hydroxy 
metabolite at 50 and 100 mg doses in alcoholic patients.  Moreover, an in vitro 
study was conducted to examine the variability of PF-5190457 metabolite 
formation in individual human liver cytosol (HLC). 
METHODS: The concentrations of PF-5190457 and its metabolite in patient 
plasma samples obtained through phase 1 b clinical trials were determined using 
a validated LC-MS/MS method. Previous studies from our group has 
demonstrated that PF-5190457 is metabolized by aldehyde oxidase (AOX1) to a 
major hydroxyl metabolite.  To determine the variability of hydroxy metabolite 
formation, the substrate was incubated in n=10 individual HLCs. The AOX1 
protein levels were obtained by mass spectroscopy using a label free quantitation 
approach and information dependent acquisition. 
RESULTS: The half-life of parent and metabolite was found to be approximately 
6 and 13 h respectively for both doses. The CLint in HLC for PF-5190457 ranged 
from 0.4 – 7.1 µL/min/mg protein with 17-fold variability. The estimated AOX1 
protein expression were much closer ranging from 16.8 - 44.1 pmol/mg (2.6-fold 
variability). The correlation between AOX1 protein expression and aldehyde 
oxidase (AO) activity was poor. 
CONCLUSION: The pharmacokinetics of PF-5190457 and its major metabolite 
was evaluated after oral administration of 50 and 100 mg and importantly the 
half-life of the metabolite was found to be longer than the parent. Inter-individual 
variability in the hydroxy metabolite formation was observed in HLC indicating a 
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need to assess the influence of various demographic factors on a larger number 
of samples.  
Keywords 
Aldehyde oxidase, alcoholism, IDA Information dependent acquisition, HLC 
Human liver cytosol, PF-5190457, XO Xanthine Oxidase 
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Introduction 
PF-5190457 is a ghrelin receptor inverse agonist and is currently undergoing 
clinical trials to treat alcoholism and type 2 diabetes mellitus [1-3]. This drug was 
originally developed by Pfizer and the tolerability of the compound in healthy 
volunteers was evaluated. The pharmacokinetics of the drug in healthy 
volunteers (n=35) was determined at single (2, 10, 40, 50, 100, 150, and 300 mg) 
and multiple (2, 10, 40 and 100 mg BID for two weeks). The absorption of the 
PF-5190457 was observed to be rapid and the elimination half-life was found to 
be ~9 h [4].  
We have previously showed that PF-5190457 is metabolized to a hydroxy 
metabolite by the molybdenum co-factor containing enzymes AO and xanthine 
oxidase (XO). The contribution of AO in the metabolism of the drug was identified 
to more dominant (manuscript II). AO enzyme is gaining increasing importance in 
the metabolism and clearance of new drug entities in the recent years [5, 6]. 
There are various in vitro studies in S9 fraction, cytosol and hepatocytes 
demonstrating high interindividual variability in AO activity with use of various 
substrates [7-9].  For example, AO activity measured in cytosol from same 
donors using carbazeran, zoniporide and phthalazine as probe substrates varied 
90, 42 and 17-fold respectively [10]. 
In the present paper, we determine the concentration of PF-5190457 and its 
hydroxy metabolite in alcoholic patients (N=12) enrolled in a phase 1b clinical 
study in subjects with alcohol use disorder. In an effort to address the variability 
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of PF-5190457 metabolism with respect to AO activity, the metabolite formation 
was measured in HLC from 10 individual donors. In addition, the measured 
activity was correlated with the expression of AO protein and the characteristics 
of HLC donors were examined to understand the impact of demographic 
variables such as age, gender, ethnicity, smoking, alcohol, medical history. 
 
Materials and methods 
Chemicals and reagents 
PF-5190457 (Mw 512.67) and tacrine (Mw 198.26) were obtained from Sigma-
Aldrich (St. Louis, MO, USA). PF-6870961 (Hydroxy metabolite Mw 528.23) was 
synthesized as described in manuscript II. LC-MS grade methanol and formic 
acid were obtained from Fisher Scientific (FairLawn, NJ, USA). Blank K2EDTA 
human plasma from six subjects (three male, three female) were obtained from 
Bioreclamation (IVT Inc., Westbury, NY, USA).  
Pharmacokinetic study in Alcohol Dependent Subjects 
Phase 1b clinical study of PF-5190457 was conducted in non treatment seeking 
alcohol dependent individuals at NIH clinical center at Bethesda. Men and 
women between 21 – 65 years were eligible. The study was approved by the 
University of Rhode Island Institutional Review Board HU# 123.172. The 
participants of the study have filled out the informed consent form prior to the 
study. Briefly, the key inclusion criteria were heavy drinking (on an average for 
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men – 21 drinks and women – 14 drinks a week) and good health which was 
confirmed by medical history, physical examination, ECG, blood/urine lab tests. 
Moreover, the female subjects must be of non-childbearing potential, and male 
subjects must follow contraception for a period of 28 days after dosing. Briefly the 
key exclusion criteria were interest in receiving treatment for alcohol use 
disorder, diagnosis of substance dependence (other than alcohol and/or 
nicotine), schizophrenia, bipolar disorder, or other psychoses, clinically significant 
medical abnormalities, heart rate >100 at screening on two separate 
measurements given potential of study medication to increase heart rate and BMI 
less than or equal to 18.5.  
This phase 1b study was a within-subject design and a single blind dose-
escalating placebo controlled inpatient study.  Subjects (N=12) were admited to 
the clinical research center (NIH clinical center at Bethesda) for three visits 
(placebo, a dose of 50 mg and a dose of 100 mg). The subjects received PF-
5190457 orally as solution every twelve hours for a total of 5 doses. Blood 
samples for pharmacokinetics analysis were collected in the morning of the third 
day of hospital stay after the administration of a fifth dose of PF-5190457 at 
various time points (0, 15, 30, 45, 60, 90, 120, 150,180, 210, 240, 360, 480, 1350 
and 1440 min). The concentration of PF-5190457 and its hydroxy metabolite (PF-
6870961) in plasma were measured using an LC-MS/MS assay specifically 
developed and validated for the purpose of this study as described in manuscript 
I.  Briefly, the plasma extraction method involved simple precipitation in methanol 
and samples were analyzed using an Acquity UPLC system coupled with Xevo 
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TQ MS detector (Waters Corp, Milford, MA, USA). The pharmacokinetic 
parameters were determined using non-compartmental analysis. Cmax (maximum 
observed drug concentration during the study), AUC0–24 is area under the plasma 
concentration–time curve measured for 24 h, using the trapezoidal rule, AUClast-∞ 
is based on the last observed concentration extrapolated to infinity time 
(Cplast/k), k is rate constant, AUC0–∞ is area under the curve from time 0 
extrapolated to infinite time (AUC0–24 + AUClast-∞), Tmax is time to observe 
maximum drug concentration, and T1/2 is half-life determined by 0.693/K). The 
apparent volume of distribution and clearance were calculated using the relations 
Vz/F= Dose / (AUC0–∞* k) and Cl/F = Dose / AUC0–∞ respectively [11]. The 
pharmacokinetic parameters were evaluated for each subject at respective doses 
(50 and 100 mg). 
 
Human Liver Selection for In vitro studies 
The livers (n=10) for the in vitro study were selected from the existing novel 
human liver bank (n=104) in the lab purchased from Sekisui XenoTech LLC 
(Kansas City, KS). The primary criteria for selecting the livers in this study were 
based on ethnicity (African American - AA, Caucasian - CC). It is a common 
practice to perfuse livers with University of Wisconsin solution containing 
allopurinol (a well-known XO inhibitor) and its primary metabolite oxypurinol and 
they have shown to completely inhibit XO activity [12]. From our liver bank, we 
identified that only n=9 out of 104 were allopurinol free and none of the donors 
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were African American. For the purpose of uniformity, the livers selected for the 
present study were containing allopurinol/oxypurinol which was detected by mass 
spectrometry analysis as described in Manuscript II. The livers were well 
characterized and documented for demographic factors like age, gender, BMI, 
weight of body and liver, ethnicity, alcohol consumption, smoking, along with 
medical history for diabetes and non-alcoholic fatty liver disease. Table 1 shows 
demographic characteristics of donors. 
Human liver cytosol Incubations 
The procedure that was used to prepare liver cytosol has been described 
elsewhere [13]. The hydroxy metabolite formation was examined in the 10 
individual HLC selected over the PF-5190547 concentration range of 0 - 400 µM 
and cytosolic protein concentration of 0.1 mg/ml. All experiments were performed 
in triplicates. The details for incubation conditions and subsequent LC-MS/MS 
analysis of cytosolic samples in Acquity UPLC coupled to Xevo TQ MS detector 
(Waters Corp, Milford, MA, USA) for determining the kinetic parameters are 
described in Manuscript II. The velocity of the reaction was calculated from 
Michealis Menton equation and CLint (intrinsic clearance) was calculated as 
Vmax/Km where Vmax is maximum rate of product formation and Km is Michaelis-
Menten constant (substrate concentration required for an enzyme to reach one-
half of its maximum velocity). 
Estimation of AOX1 protein expression in Human liver cytosol using LC-
MS/MS 
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AOX1 levels (pmol/mg) in cytosolic fractions were determined using a label free 
approach on mass spectrometry as described in Manuscript III. Briefly, the 
digestion of proteins in cytosolic samples was performed using trypsin and the 
resulting peptides were analyzed using information dependent acquisition (IDA) 
mode on an AB Sciex TripleTOF 5600+ mass spectrometer. The subsequent 
data analysis was performed using MaxQuant (Version 1.5) proteomics software 
for protein (AOX1) identification by searching against UniProt human protein 
database (updated Oct 2016) and quantification. The maximum false peptide 
discovery rate was specified as 0.01.  AOX1 protein was calculated based on the 
raw spectral protein intensity from label-free quantification (LFQ) intensities of the 
MaxQuant software output using the “Total Protein Approach” (TPA). 
Statistical analysis 
Statistical analysis was performed with SPSS version 24 (IBM Analytics, Armonk, 
NY), and Prism® version 6 (GraphPad Software Inc., San Diego, CA) was used 
for graphing and calculation of kinetic parameters (Vmax and Km).  Since most of 
the datasets were not normally distributed, nonparametric methods were 
generally used for statistical analyses.  Non-parametric Mann-Whitney U test (2-
tailed) was used to compare the effect of ethnicity and other demographic factors 
on enzyme activity and AOX1 levels. The correlation was studied using 
nonparametric Spearman correlation analysis.  
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Results  
Pharmacokinetics analysis 
The validated LC-MS/MS method (Manuscript I) has been successfully applied to 
measure the concentrations of PF-5190547 and its hydroxy metabolite after oral 
administration of the drug at 50 mg and 100 mg in human plasma. The mean 
concentration versus time profiles of the analytes in human plasma are shown in 
Figure 1 a and b. The plasma concentration ranges of the analytes were 
measurable within their calibration curves. The concentrations of PF-5190547 
and its hydroxy metabolite ranged from 2.8 to 213.3 ng/mL and 3.9 to 73.8 ng/mL 
for 50 mg dose and 3.5 to 813.7 ng/mL, and 6.6 to 124.8 ng/mL for 100 mg dose, 
respectively. Pharmacokinetic details for the area under the curve from initial 
time to infinity (AUC0–∞), Cmax, Tmax, Vz/F, Cl/F and t1/2 are shown in Table 2 for 
both 50 and 100 mg doses. The half-life for the metabolite (14.7 ± 2.1 and 12.8 ± 
2.2 h) at both the doses (50 and 100 mg) was observed to be longer in 
comparison to the parent (6.2 ± 1 and 5.8 ± 0.5 h). 
Individual PF-5190457 metabolism in HLC 
Formation of hydroxy metabolite of PF-5190457 in this study was mediated by 
AO as HLCs in the selected livers were devoid of XO activity. In general, 
individual variation in AO activity (Figure 2) was observed in all kinetic 
parameters for the hydroxy metabolite formation (Table 3). Km and Vmax values 
ranged from 8.1 to 68.3 µM and 0.02 to 0.41 nmol/min/mg protein respectively. 
CLint was found to be between 0.4 – 7.1 µL/min/mg (~ 17 fold variability). African 
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American donors exhibited marginally lower AO activity in comparison to 
Caucasian donors. However, no significant association (P>0.1,) was observed 
between ethnicity and AO activity (Figure 3a). The effect of other demographic 
factors was examined and no significant relationship was observed. 
Nevertheless, the effect of smoking on AO activity was observed to be significant 
with p<0.017 (Figure 4a). The limitation of this study was small sample size as 
there were only n=3 out of 10 livers were obtained from non-smoker individuals. 
Expression of AOX1 protein in HLC and correlation to In vitro AO activity 
The AOX1 levels obtained from data analysis using MaxQuant TPA approach 
ranged from 16.8 – 44.2 pmol/mg with 2.6 fold difference (Figure 5) across the 
examined HLCs. There was no significant effect of ethnicity (Figure 3b) and 
smoking (Figure 4b) on AOX1 levels observed. Moreover, other demographic 
factors mentioned in Table 1 did not significantly influence AOX1 levels. The AO 
activity characterized by rate of formation of hydroxy metabolite showed a weak 
correlation (Figure 6) (Spearman r = 0.2 and p>0.5) with AOX1 protein levels.  
 
Discussion 
The in vivo study evaluated pharmacokinetics of PF-5190457 and its hydroxy 
metabolite in alcohol dependent subjects. The pharmacodynamics of the drug in 
the same study population is evaluated by our lab and will be discussed 
elsewhere. Previously, published study determined PF-5190457 
pharmacokinetics in healthy subjects [4] and the half-life of the parent was 
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observed to be higher in comparison to our study in alcoholic subjects (~9 vs ~6 
hours) whereas, the other parameters (Cmax, Tmax) were comparable. It could be 
because of differences in blood sampling points or differences in the population 
(healthy vs alcoholic subjects).  
The kinetics of major hydroxyl metabolite was not reported previously. The 
findings from the present study also indicate that the half-life of the hydroxy 
metabolite in heavy drinkers was higher in comparison to the parent drug. The 
higher exposure of the metabolite in the body could be of an advantage if the 
metabolite would have any pharmacological significance and further evaluations 
with respect to safety profile and byproducts of the hydroxy metabolite are 
necessary. The clinical study for PF-5190457 recruited n=12 subjects and the 
majority of the subjects where African American (n=11). The differences in 
ethnicity could affect the pharmacokinetics and subsequent pharmacodynamics 
of the drug [14, 15].  In addition, the variability of pharmacokinetic parameters is 
largely explained by genetic variation in metabolizing enzymes [16], disease 
state, physiological and environmental factors [17, 18]. The primary objective for 
the in vitro study in the present paper was to determine differences in metabolism 
of PF-5190457 with respect to ethnicity (African American vs. Caucasians) and 
inter-individual variability. 
PF-5190457 is predominantly metabolized by AO enzyme (Manuscript II). Wide 
variability has been reported for substrates metabolized by AO and the 
metabolism has demonstrated to be highly substrate dependent with high donor  
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to donor variability [10, 19, 20]. An example, the AO activity was measured using 
different probe substrates N-[(2-dimethylamino) ethyl] acridine-4-carboxamide 
(DACA) and benzaldehyde in the same HLC donors (n=13). The CLint with 
respect to DACA and benzaldehyde was 18-fold and 5-fold respectively across 
the individual donors [21]. In our study, the CLint varied 17-fold for PF-5190457 
across individual HLC. Further, weak correlation between the AOX1 protein 
levels and AO activity was observed which were in accordance with findings from 
another in vitro study in HLC [10]. Few studies published to determine correlation 
between AO protein and activity. The hydroxy metabolite formation was found to 
be reduced in AA but the non-significant change could be because of the small 
sample size of HLC. There is only one study so far, showing the influence of 
ethnicity on AO activity in cryopreserved hepatocytes using O6-benzylguanine as 
a probe substrate which showed no significant effect between AA (n=7) vs CC 
(n=50) on AO activity. The above-mentioned study too had several livers from AA 
donors.  Further exploration of other demographic factors on PF-5190457 
metabolism indicated smoking could lead to low AO activity but study in large 
sample size of donors would be essential for confident results. There is only 
limited information published on the impact of smoking on AO protein and 
activity. One study discussed no relationship between AO activity and smoking 
but it was based on 1 out of 13 HLC donors with tobacco use [21]. In one other 
study AO activity in large sample size (75 donors) was assessed using 
hepatocytes and the livers were characterized for tobacco use but the effect of 
smoking was not mentioned [22]. It is also known that nicotine is primarily 
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metabolized by CYP1A2 to an iminium ion and then the second step of 
metabolism primarily involves AO enzyme [23-25]. Fu et al. showed chronic 
alcohol use in (n=2) HLC donors could influence the AO activity but the small 
sample size was a limitation. The effect of both smoking and alcohol use could 
have a significant impact on AO activity and warrants further examination in a 
larger number of samples. 
AO protein is a homodimer and disruption in homodimer formation can affect AO 
activity [26]. Other reasons for variation in AO activity could be protein misfolding 
or genetic polymorphism [27]. Genetic polymorphism of hAOX1 was studied in 
Italian population and the presence of functionally inactive hAOX1 allelic variants 
enzymes was determined [26]. To the best of our knowledge there are no studies 
conducted exclusively in AA population to assess the presence of allelic variants. 
One study determined the impact of common single nucleotide polymorphism on 
the AO activity in 75 donors in which there were only seven African American 
and 50 Caucasians and the rest were Hispanic. The study showed no statistical 
significance for polymorphism on AO activity [22]. 
Dietary constituents could also influence the AO activity [28]. AO enzyme 
contains iron along with molybdopterin cofactor and flavin adenine dinucleotide. It 
has been reported that iron deficiency could lead to lower AO activity as reported 
in a rat study. AO is the main enzyme for serotonin degradation and rats on iron 
deficient diet exhibited significantly increased concentrations of serotonin. The 
levels of serotonin reverted back to normal when the rats were supplemented 
with iron [29]. It is known that AO and XO enzyme share closely related  
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structures. The XO expression and activity in lung were reduced in rats fed on an 
iron-depleted diet and increased in rats supplemented with iron [30]. AO belongs 
to the same family iron supplementation could be one of the reasons for the 
variability observed in AO activity.  
The findings from the present study could be important as variability in PF-
5190457 was observed across individual HLC. Since multiple factors could be 
contributing to variability in AO activity, larger sample size is necessary to 
address the connections.  
In conclusion, the manuscript describes the successful application of LC-MS/MS 
method to a pharmacokinetic study of PF-5190547 at 50 and 100 mg in healthy 
volunteers in phase 1b clinical trials to treat alcoholism. The in vitro study shows 
donor variability in hydroxylation of PF-5190457 in human liver cytosol. 
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FIGURE LEGENDS 
Figure 1 (a) and (b) Plasma concentration time profiles for parent (PF-
5190547) and hydroxy metabolite after the administration of 50 and 100 mg 
dose respectively. Data are shown as mean ± SD at each time point. 
Figure 2 Bar chart demonstrating AO activity in individual human liver 
cytosol. AO activity was characterized by hydroxylation of PF-5190457 across 
n=10 human liver cytosol. The data was found to be non normally distributed with 
a 20 fold variability. 
Figure 3 (a) Effect of ethnicity on AO activity and (b) AOX1 levels. AO 
activity in African American, AA (n=5) was observed to be lower in comparison to 
Caucasians, CC (n=5) but not significantly different (p>0.1). AOX1 proteins levels 
were observed to be not significantly different across both the groups  
Figure 4 (a) Effect of smoking on AO activity and (b) AOX1 levels. AO 
activity in smokers (n=7) was observed to be significantly lower (p<0.017 Mann 
Whitney U test). in comparison to and non-smokers (n=3), CC (n=5). AOX1 
proteins levels were observed to be not significantly different across both the 
groups. 
Figure 5 Distribution of AOX1 protein levels in 10 individual human liver 
cytosol. The range of AOX1 levels was between 16 – 44 pmol/mg as determined 
by label free quantification approach using information dependent acquisition on 
mass spectroscopy. 
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Figure 6. Correlation between AO activity and AOX1 levels (pmol/mg). Open 
circles represent Caucasians and closed circles for African Americans. The 
equation of the line for the best fit was generated by least square linear 
regression analysis. Statistical significance of the correlations was determined by 
the Spearman correlation test. A weak correlation (p>0.5) was observed between 
AO activity (hydroxy metabolite of PF-5190457) formation and AOX1 levels was 
observed.  
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Table IV-1. Demographics and baseline characteristics of the human 
subjects 
Number (N) 12 
Females (n, %)  1 (8%) 
Age (years) 
Range 
M ± SD 
Median 
  
23-58 
40.5 ± 13.1 
40.0 
Race/Ethnicity (%) 
African-Americans 
Caucasians 
  
11 (91.7%) 
1 (8.3%) 
Cigarette smoking Status (n, %) 
           Smoker 
           Non-Smoker 
  
9 (75.0%) 
3 (25.0%) 
DSM-IV diagnosis of alcohol dependence (n, %) 11 (91.7%) 
BMI, Kg/m2, (M ± SD) 27.1 ± 4.7 
90-day baseline average drinks/drinking day, (M ± SD) 10.7 ± 4.2 
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Table IV-2. Demographic and donor data details 
ID Gender Age Ethnicity Smoking Drug_Use 
Medical 
History 
HLC_01 M 44 AA Yes Yes Diabetes 
HLC_02 F 49 AA Yes No Diabetes 
HLC_03 M 48 AA Yes Yes No 
HLC_04 M 23 AA Yes Yes No 
HLC_05 F 49 AA Yes No Diabetes 
HLC_06 F 78 CC No No Diabetes 
HLC_07 F 53 CC No No Diabetes 
HLC_08 M 59 CC Yes No No 
HLC_09 M 44 CC No Yes No 
HLC_10 M 53 CC Yes No Diabetes 
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Table IV-3. Summary of pharmacokinetic parameters  
a. 50 mg PF-5190457 dose (mean ± SD, n = 12) 
Dose-50 mg  Parent (PF-5190457) Hydroxy Metabolite 
AUC (0-∞) (ng.min)/mL  53184.8 ± 20694.8  33945.5 ± 9753.4  
Cmax (ng/mL)  134.3 ± 43.8  39.8 ± 14.1  
Tmax (min)  56.2 ± 24  56.2 ± 12.9  
Half life (h)  6.2 ± 1  14.7 ± 2.1  
CL/F (L/h)  60.7 ± 16.8  93.6 ± 28.8  
Vz/F(L) 554.7 ± 156.7  2069.4 ± 781.2  
 
b. 100 mg PF-5190457 dose (mean ± SD, n = 12) 
Dose-100 mg  
Parent (PF-
5190457) 
Hydroxy Metabolite 
AUC (0-∞) (ng.min)/mL  108528.7 ± 64556.3  57497.6 ± 18588.6  
Cmax (ng/mL)  305.6 ± 189.4  76.2 ± 23.1  
Tmax (min)  50 ± 28.8  68.7 ± 48  
Half life (h)  5.8 ± 0.5  12.8 ± 2.2  
CL/F (L/h)  70 ± 40.2  111.6 ± 33.9  
Vz/F(L) 604.7 ± 364.5  2162.7 ± 930.9  
 
AUC = area under the plasma concentration time curve, Cmax = maximum 
observed plasma concentration, Tmax = time of Cmax, Cl/F = Apparent 
Clearance, Vz/F = Apparent volume of distribution 
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Table IV-4. Kinetic parameters for hydroxy metabolite formation of PF-5190457 
in individual human liver Cytosol 
ID 
Vmax 
(nmol/min/mg) 
Km 
(µM) 
CLint 
(µL/min/mg) 
AOX1 
(pmol/mg) 
HLC_01 0.06 17.7 3.4 25.70 
HLC_02 0.13 27.9 4.6 43.40 
HLC_03 0.14 57.1 2.5 23.21 
HLC_04 0.07 43.7 1.7 20.54 
HLC_05 0.04 8.1 5.3 44.29 
HLC_06 0.23 42.5 5.4 25.37 
HLC_07 0.24 36.1 5.4 32.06 
HLC_08 0.02 68.3 0.4 16.83 
HLC_09 0.41 58.1 7.1 30.37 
HLC_10 0.15 43.4 2.0 22.47 
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 Figure IV-1 (a) and (b). 
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Figure IV-2.  
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Figure IV-3. 
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Figure IV-4. 
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Figure IV-5.  
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Figure IV-6. 
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